Document:

<PAGE>

                                                                    Exhibit 10.7

                       SIXTH AMENDMENT TO CREDIT AGREEMENT
                     AND FIRST AMENDMENT TO PLEDGE AGREEMENT

                  SIXTH AMENDMENT TO CREDIT AGREEMENT AND FIRST AMENDMENT TO
PLEDGE AGREEMENT (collectively, this "Amendment") dated as of March 30, 2001,
among FAIRPOINT COMMUNICATIONS, INC. (f/k/a MJD Communications, Inc.), a
Delaware corporation (the "Borrower"), the lenders from time to time party to
the Credit Agreement referred to below (the "Lenders"), FIRST UNION NATIONAL
BANK, as Documentation Agent (the "Documentation Agent"), BANK OF AMERICA, N.A.
(f/k/a Bank of America National Trust and Savings Association, successor by
merger to Bank of America, N.A. f/k/a Nationsbank, N.A. successor by merger to
NATIONSBANK OF TEXAS, N.A.), as Syndication Agent (the "Syndication Agent"),
BANKERS TRUST COMPANY, as Administrative Agent (the "Administrative Agent" and,
together with the Documentation Agent and the Syndication Agent, collectively,
the "Agents") and BANKERS TRUST COMPANY, as Pledgee under the Pledge Agreement
referred to below (the "Pledgee"). Unless otherwise indicated, all capitalized
terms used herein and not otherwise defined shall have the respective meanings
provided such terms in the Credit Agreement referred to below.

                              W I T N E S S E T H:
                               - - - - - - - - - -

                  WHEREAS, the Borrower, the Lenders and the Agents are parties
to a Credit Agreement, dated as of March 30, 1998 (as amended, modified or
supplemented to but not including the date hereof, the "Credit Agreement");

                  WHEREAS, the Borrower, various Subsidiaries of the Borrower
and the Pledgee are parties to a Pledge Agreement, dated as of March 30, 1998
(as amended, modified or supplemented to, but not including, the date hereof,
the "Pledge Agreement"); and

                  WHEREAS, subject to the terms and conditions of this
Amendment, the parties hereto wish to amend the Credit Agreement and the Pledge
Agreement, in each case as herein provided;

                  NOW, THEREFORE, it is agreed:

I.       AMENDMENTS TO CREDIT AGREEMENT.

                  1. Section 1.01(a) of the Credit Agreement is hereby amended
by deleting said Section in its entirety and inserting the following new Section
1.01(a) in lieu thereof:

                  "(a) Loans under the Initial B Term Facility (each, an
         "Initial B Term Loan" and, collectively, the "Initial B Term Loans")
         (i) shall be made to the Borrower pursuant to one or more drawings on
         and after the Closing Date and prior to the Initial B Termination Date,
         provided that Initial B Term Loans incurred pursuant to Initial B Term
         Commitments created pursuant to an Initial B Term Commitment Renewal
         shall not be subject to
<PAGE>

         the foregoing but shall be made within the time frame specified in the
         definition of Initial B Term Commitment Renewal, (ii) except as
         hereinafter provided, may, at the option of the Borrower, be incurred
         and maintained as, and/or converted into, Base Rate Loans or Eurodollar
         Loans, provided that all Initial B Term Loans made as part of the same
         Borrowing shall, unless specifically provided herein, consist of Loans
         of the same Type and (iii) shall not exceed in aggregate principal
         amount for any Lender in respect of any incurrence of Initial B Term
         Loans the Initial B Term Commitment, if any, of such Lender as in
         effect immediately prior to such incurrence. Once repaid, Initial B
         Term Loans may not be reborrowed, provided that Initial B Term Loans
         may be subsequently incurred to the extent of the Initial B Term
         Commitments created pursuant to the Initial B Term Commitment
         Renewal.".

                  2. Section 1.01(b) of the Credit Agreement is hereby amended
by deleting said Section in its entirety and inserting the following new Section
1.01(b) in lieu thereof:

                  "(b) Loans under the Initial C Term Facility shall be made
         pursuant to the Total Initial C Term Commitment (each, an "Initial C
         Term Loan-Floating Rate" and, collectively, the "Initial C Term
         Loans-Floating Rate") and pursuant to the CoBank Commitment (each, a "C
         Term Loan-Fixed Rate" and, collectively, the "C Term Loans-Fixed
         Rate"), with (A) the Initial C Term Loans-Floating Rate (i) to be made
         to the Borrower pursuant to a single drawing on the Closing Date (and
         not thereafter), (ii) except as hereinafter provided, and, in any
         event, at the option of the Borrower, to be incurred and maintained as,
         and/or converted into, Base Rate Loans or Eurodollar Loans, provided
         that all Initial C Term Loans-Floating Rate made as part of the same
         Borrowing shall, unless specifically provided herein, consist of Loans
         of the same Type and (iii) not to exceed in aggregate principal amount
         for any Lender at the time of incurrence of Initial C Term
         Loans-Floating Rate on the Closing Date the Initial C Term Commitment,
         if any, of such Lender as in effect on such date immediately prior to
         such incurrence and (B) the C Term Loans-Fixed Rate to be made to the
         Borrower by CoBank on the Closing Date (and not thereafter) by
         converting the CoBank Continuing Loans into C Term Loans-Fixed Rate in
         the aggregate amount of the CoBank Commitment. Once repaid, Initial C
         Term Loans-Floating Rate and C-Term Loans-Fixed Rate may not be
         reborrowed.".

                  3. Section 1.01 of the Credit Agreement is hereby amended by
inserting the following new clauses (e) and (f) at the end of said Section:

                  "(e) Subject to Section 1.14 and the other terms and
         conditions set forth herein, Loans under the Incremental B Term
         Facility (each, an "Incremental B Term Loan" and, collectively, the
         "Incremental B Term Loans") (i) shall be made to the Borrower pursuant
         to a single drawing on the respective Incremental B Term Borrowing Date
         (which date, in any event, shall be the date of effectiveness of the
         applicable Incremental Term Loan Commitment Agreement pursuant to which
         such Incremental B Term Loans are to be made and shall not be later
         than the Incremental Term Commitment Termination Date); (ii) except as
         hereinafter provided, may, at the option of the Borrower, be incurred
         and maintained as, and/or converted into, Base Rate Loans or Eurodollar
         Loans, provided that

                                      -2-
<PAGE>

         all Incremental B Term Loans made as part of the same Borrowing shall,
         unless specifically provided herein, consist of Loans of the same Type
         and (iii) shall not exceed in aggregate principal amount for any Lender
         in respect of any incurrence of Incremental B Term Loans the
         Incremental B Term Commitment, if any, of such Lender as in effect
         immediately prior to such incurrence. Once repaid, Incremental B Term
         Loans may not be reborrowed.

                  (f) Subject to Section 1.14 and the other terms and conditions
         set forth herein, Loans under the Incremental C Term Facility (each, an
         "Incremental C Term Loan" and, collectively, the "Incremental C Term
         Loans") (i) shall be made to the Borrower pursuant to a single drawing
         on the respective Incremental C Term Borrowing Date (which date, in any
         event, shall be the date of effectiveness of the applicable Incremental
         Term Loan Commitment Agreement pursuant to which such Incremental C
         Term Loans are to be made and shall not be later than the Incremental
         Term Commitment Termination Date); (ii) except as hereinafter provided,
         may, at the option of the Borrower, be incurred and maintained as,
         and/or converted into, Base Rate Loans or Eurodollar Loans, provided
         that all Incremental C Term Loans made as part of the same Borrowing
         shall, unless specifically provided herein, consist of Loans of the
         same Type and (iii) shall not exceed in aggregate principal amount for
         any Lender in respect of any incurrence of Incremental C Term Loans the
         Incremental C Term Commitment, if any, of such Lender as in effect
         immediately prior to such incurrence. Once repaid, Incremental C Term
         Loans may not be reborrowed.".

                  4. Section 1.05(b) of the Credit Agreement is hereby amended
by (i) inserting the text "(or, if issued after the Closing Date, be dated the
date of the issuance thereof)" immediately following the text "Closing Date" in
subclause (ii) of said Section and (ii) deleting the parenthetical appearing in
subclause (iii) of said Section and inserting the text "(or, if issued after the
Closing Date, be in a stated principal amount equal to the outstanding principal
amount of B Term Loans of such Lender at such time)" in lieu thereof.

                  5. Section 1.05(c) of the Credit Agreement is hereby amended
by (i) inserting the text "(or, if issued after the Closing Date, be dated the
date of the issuance thereof)" immediately following the text "Closing Date" in
subclause (ii) of said Section and (ii) deleting the parenthetical appearing in
subclause (iii) of said Section and inserting the text "(or, if issued after the
Closing Date, be in a stated principal amount equal to the outstanding principal
amount of C Term Loans-Floating Rate of such Lender at such time)" in lieu
thereof.

                  6. Section 1.07 of the Credit Agreement is hereby amended by
deleting the first sentence of said Section in its entirety and inserting the
following new sentence in lieu thereof:

                  "All Loans under this Agreement (other than C Term Loans-Fixed
         Rate) shall be made by the Lenders PRO RATA on the basis of their
         Initial B Term Commitments, Incremental B Term Commitments, Initial C
         Term Commitments, Incremental C Term

                                      -3-
<PAGE>

         Commitments, Revolving Commitments or Acquisition Commitments, as the
         case may be, if any.".

                  7. Section 1 of the Credit Agreement is hereby amended by
inserting the following new Section 1.14 immediately after Section 1.13
appearing therein:

                  "1.14. INCREMENTAL TERM COMMITMENTS. (a) So long as no Default
         or Event of Default then exists or would result therefrom, the Borrower
         shall, in consultation with the Administrative Agent, have the right to
         request on one or more occasions on and after the Sixth Amendment
         Effective Date and prior to the Incremental Term Commitment Termination
         Date that one or more Lenders (and/or one or more other Persons which
         will become Lenders as provided below) provide Incremental B Term
         Commitments and/or Incremental C Term Commitments and, subject to the
         terms and conditions contained in this Agreement, make Incremental B
         Term Loans and/or Incremental C Term Loans pursuant thereto, as the
         case may be, it being understood and agreed, however, that (i) no
         Lender shall be obligated to provide an Incremental Term Commitment as
         a result of any such request by the Borrower, and until such time, if
         any, as such Lender has agreed in its sole discretion to provide an
         Incremental Term Commitment and executed and delivered to the
         Administrative Agent an Incremental Term Loan Commitment Agreement as
         provided in clause (b) of this Section 1.14, such Lender shall not be
         obligated to fund any Incremental B Term Loans and/or Incremental C
         Term Loans, as the case may be, (ii) any Lender (or, in the
         circumstances contemplated by clause (vii) below, any other Person
         which will qualify as an Eligible Transferee) may so provide an
         Incremental Term Commitment without the consent of any other Lender,
         (iii) each provision of Incremental Term Commitments pursuant to this
         Section 1.14 on a given date shall be in a minimum aggregate amount
         (for all Lenders (including in the circumstances contemplated by clause
         (vii) below, Eligible Transferees who will become Lenders)) of at least
         $30,000,000, (iv) the aggregate amount of all Incremental Term
         Commitments permitted to be provided pursuant to this Section 1.14 and
         the aggregate principal amount of all Incremental Term Loans permitted
         to be made pursuant to Sections 1.01(e) and (f) shall not, in either
         case, exceed $150,000,000, (v) the relevant Incremental Term Loan
         Commitment Agreements shall specifically set forth whether the
         Incremental Term Commitments in respect thereof shall constitute either
         Incremental B Term Commitments or Incremental C Term Commitments, (vi)
         the upfront fees payable in respect of the relevant Incremental Term
         Commitments, the applicable voluntary prepayment premiums (if any)
         payable in respect of the Incremental B Term Loans and/or Incremental C
         Term Loans and the interest rate margin applicable to the Incremental B
         Term Loans and/or Incremental C Term Loans shall be as set forth in the
         relevant Incremental Term Loan Commitment Agreement; PROVIDED that in
         no event shall the applicable interest rate margin set forth in any
         such Incremental Term Loan Commitment Agreement for any Incremental
         Term Loans exceed the Applicable Base Rate Margin or Applicable
         Eurodollar Margin (in each case, as in effect on the Sixth Amendment
         Effective Date) by more than 1.00%, (vii) if, within 10 Business Days
         after the Borrower has requested the then existing Lenders (other than
         Defaulting Lenders) to provide Incremental Term Commitments pursuant to
         this Section 1.14 the Borrower has not received Incremental Term
         Commitments in an aggregate

                                      -4-
<PAGE>

         amount equal to that amount of Incremental Term Commitments which the
         Borrower desires to obtain pursuant to such request (as set forth in
         the notice provided by the Borrower as provided below), then the
         Borrower may, with the consent of the Administrative Agent (which
         consent shall not be unreasonably withheld or delayed), request
         Incremental Term Commitments from Persons which would qualify as
         Eligible Transferees hereunder in an aggregate amount equal to such
         deficiency (and with the fees to be paid to such Eligible Transferee to
         be no greater than that to be paid to the then existing Lenders
         providing Incremental Term Commitments), (viii) on each Incremental
         Term Borrowing Date, each of the Administrative Agent and each trustee
         for the Permitted Subordinated Debt shall have received an officer's
         certificate from the chief financial officer of the Borrower in form
         and substance reasonably satisfactory to the Administrative Agent,
         which certificate shall (I) contain a representation and warranty that
         (x) the Borrowing of Incremental B Term Loans and/or Incremental C Term
         Loans (and the incurrence of Liens by the Borrower and the Subsidiary
         Guarantors to secure such Obligations) do not conflict and are not
         inconsistent with and do not result in any breach or violation of, any
         of the terms, covenants, conditions or provisions of, or constitute a
         default under, any terms of any Permitted Subordinated Debt or the
         documentation governing the same, (y) after giving effect to the
         incurrence of such Loans, all of the Obligations constitute "Senior
         Debt" under the documentation governing the Permitted Subordinated Debt
         and (z) the respective Incremental Term Loans are being incurred under
         the documentation governing each incurrence of Permitted Subordinated
         Debt in reliance on the "Leverage Ratio" incurrence test referred to
         therein and subclause (II) below (and that the Borrower will not take a
         contrary position for any purpose), (II) certify that the Borrower is
         in compliance with a Leverage Ratio (as defined in the documentation
         governing the respective Permitted Subordinated Debt) of not greater
         than 7.0:1.0 (after giving PRO FORMA effect to the incurrence of the
         Incremental Term Loans to be incurred and as determined in accordance
         with the requirements of the documentation governing the respective
         Permitted Subordinated Debt), (III) be accompanied by financial
         calculations in form and substance reasonably satisfactory to the
         Administrative Agent establishing compliance with the Leverage Ratio
         referred to in preceding clause (II) and (IV) certify compliance with
         the requirements of the documentation governing all Permitted
         Subordinated Debt and all applicable covenants contained therein; and
         (ix) all actions taken by the Borrower pursuant to this Section 1.14
         shall be done in coordination with the Administrative Agent.

                  (b) At the time of any provision of Incremental Term
         Commitments pursuant to this Section 1.14, (i) the Borrower, the
         Administrative Agent and each such Lender or other Eligible Transferee
         (each, an "Incremental Term Lender") which agrees to provide an
         Incremental Term Commitment shall execute and deliver to the
         Administrative Agent an Incremental Term Loan Commitment Agreement
         substantially in the form of Exhibit L (appropriately completed), with
         the effectiveness of such Incremental Term Lender's Incremental Term
         Commitment to occur upon delivery of such Incremental Term Loan
         Commitment Agreement to the Administrative Agent and the payment of any
         fees (including, without limitation, any fees payable pursuant to
         clause (ii) below) required in connection therewith, (ii) the
         Administrative Agent shall receive from the Borrower (or,

                                      -5-
<PAGE>

         to the extent agreed to by the Borrower and the respective Incremental
         Term Lender, from such respective Incremental Term Lender) the payment
         of a non-refundable fee of $3,500 for each Eligible Transferee which
         becomes a Lender pursuant to this Section 1.14 and (iii) the Borrower
         shall deliver to the Administrative Agent an opinion or opinions, in
         form and substance reasonably satisfactory to the Administrative Agent,
         from counsel to the Borrower reasonably satisfactory to the
         Administrative Agent and dated such date, covering such of the matters
         set forth in the opinions of counsel delivered to the Administrative
         Agent on the Closing Date pursuant to Section 4.01(b) as may be
         reasonably requested by the Administrative Agent, and such other
         matters as the Administrative Agent may reasonably request (including
         an opinion as to no conflict with all Permitted Subordinated Debt and
         the documentation governing the same). The Administrative Agent shall
         promptly notify each Lender as to the effectiveness of each Incremental
         Term Loan Commitment Agreement, and (i) at such time Annex I shall be
         deemed modified to reflect the Incremental B Term Commitments and/or
         Incremental C Term Commitments, as the case may be, of such Incremental
         Term Lenders and (ii) to the extent requested by such Incremental Term
         Lenders, B Term Notes and/or C Term Notes-Floating Rate will be issued,
         at the Borrower's expense, to such Incremental Term Lenders, to be in
         conformity with the requirements of Section 1.05 (with appropriate
         modifications) to the extent needed to reflect the new Incremental Term
         Loans made by such Incremental Term Lenders.

                  (c) In connection with each incurrence of Incremental B Term
         Loans pursuant to Section 1.01(e) or Incremental C Term Loans pursuant
         to Section 1.01(f), the Lenders and the Borrower hereby agree that,
         notwithstanding anything to the contrary contained in this Agreement,
         the Borrower and the Administrative Agent may take all such actions as
         may be necessary to ensure that all Lenders with outstanding B Term
         Loans and C Term Loans-Floating Rate, as the case may be, continue to
         participate in each Borrowing of outstanding B Term Loans and C Term
         Loans-Floating Rate (after giving effect to the incurrence of
         Incremental B Term Loans or Incremental C Term Loans pursuant to
         Section 1.01(e) or (f), as the case may be) on a PRO RATA basis,
         including by adding the Incremental B Term Loans or the Incremental C
         Term Loans to be so incurred to the then outstanding Borrowings of B
         Term Loans or C Term Loans-Floating Rate, as the case may be, on a PRO
         RATA basis even though as a result thereof such new Incremental B Term
         Loan or Incremental C Term Loan, as the case may be (to the extent
         required to be maintained as Eurodollar Loans), may effectively have a
         shorter Interest Period than the then outstanding Borrowings of B Term
         Loans or C Term Loans-Floating Rate, as the case may be, and it is
         hereby agreed that (x) to the extent any then outstanding Borrowings of
         B Term Loans or C Term Loans-Floating Rate that are maintained as
         Eurodollar Loans are affected as a result thereof, any costs of the
         type described in Section 1.11 incurred by such Lenders in connection
         therewith shall be for the account of the Borrower or (y) to the extent
         the Incremental B Term Loans and Incremental C Term Loans to be so
         incurred are added to the then outstanding Borrowings of B Term Loans
         or C Term Loans-Floating Rate, as the case may be, which are maintained
         as Eurodollar Loans, the Lenders that have made such additional
         Incremental B Term Loans or Incremental C Term Loans, as the case may
         be, shall be entitled to receive an effective

                                      -6-
<PAGE>

         interest rate on such additional Incremental B Term Loans or
         Incremental C Term Loans, as the case may be, as is equal to the
         Eurodollar Rate as in effect two Business Days prior to the incurrence
         of such additional Incremental B Term Loans or Incremental C Term
         Loans, as the case may be, plus the then Applicable Eurodollar Margin
         for such Term Loans until the end of the respective Interest Period or
         Interest Periods with respect thereto."

                  8. Section 2.01 of the Credit Agreement is hereby amended by
inserting the following new clause (f) at the end of said Section:

                  "(f) All voluntary prepayments of principal of B Term Loans
         and C Term Loans-Floating Rate, in each case made on or after the
         occurrence of the first Incremental Term Borrowing Date to occur after
         the Sixth Amendment Effective Date and prior to the second anniversary
         of such Incremental Term Borrowing Date, will be subject to payment to
         the Administrative Agent, for the ratable account of each Lender with
         outstanding B Term Loans and each Lender with outstanding C Term
         Loans-Floating Rate, of a fee as follows: (x) if prior to the first
         anniversary of the first Incremental Term Borrowing Date to occur after
         the Sixth Amendment Effective Date, an amount equal to the Specified
         Prepayment Premium Percentage of the aggregate principal amount of such
         prepayment and (y) if payable on or after the first anniversary of the
         first Incremental Term Borrowing Date to occur after the Sixth
         Amendment Effective Date and prior to the second anniversary of such
         Incremental Term Borrowing Date, an amount equal to the Specified
         Prepayment Premium Percentage of the aggregate principal amount of such
         prepayment. Such prepayment fees shall be due and payable upon the date
         of any voluntary prepayment of such Term Loans.".

                  9. Section 2.02(a) of the Credit Agreement is hereby amended
by (i) deleting the comma appearing at the end of clause (x) of said Section and
inserting the word "and" in lieu thereof and (ii) deleting the text "any
reduction of the Total Revolving Commitment or Total Acquisition Commitment, as
the case may be, pursuant to this Section 2.02(a) shall reduce the then
remaining Scheduled Reductions applicable thereto PRO RATA and (z)" appearing in
said Section.

                  10. Section 2.03(a) of the Credit Agreement is hereby amended
by deleting the text "The Total Commitment (and the Commitment of each Lender)"
appearing in said Section and inserting the text "The Total Initial B Term
Commitment, the Total Initial C Term Commitment, the Co-Bank Commitment, the
Total Revolving Commitment and the Total Acquisition Commitment (and the Initial
B Term Commitment, Initial C Term Commitment, Co-Bank Commitment, Revolving
Commitment and Acquisition Commitment of each Lender with such a Commitment)" in
lieu thereof.

                  11. Section 2.03(b) of the Credit Agreement is hereby amended
by deleting said Section in its entirety and inserting the following new Section
2.03(b) in lieu thereof:

                  "(b) The Total Initial B Term Commitment shall (i) be reduced
         on the date any Initial B Term Loans are incurred in an amount equal to
         the aggregate principal amount

                                      -7-
<PAGE>

         of Initial B Term Loans so incurred, (ii) terminate in its entirety (to
         the extent not theretofore terminated) at 5:00 P.M. (New York time) on
         the Initial B Termination Date, whether or not any Initial B Term Loans
         are incurred on such date, (iii) until terminated in full, be reduced
         on each day on which Initial B Term Loans, if still outstanding, would
         be required to be repaid pursuant to Sections 3.02(A)(c), (e) and (f)
         by the amount, if any, by which the amount required to be applied
         pursuant to said Sections to repay Initial B Term Loans (determined as
         if an unlimited amount of Initial B Term Loans were actually
         outstanding) exceeds the aggregate principal amount of Initial B Term
         Loans being repaid, (iv) terminate in its entirety (to the extent not
         theretofore terminated) on the date of the initial issuance of any
         Permitted Subordinated Debt, (v) terminate in its entirety on the day
         on which a Change of Control occurs and (vi) be increased after any
         Initial B Term Loans have been mandatorily repaid pursuant to Section
         3.02 or the Total Initial B Term Loan Commitment has been reduced
         pursuant to clause (iii) or (iv) above in the aggregate amount of such
         repayment and/or reduction to the extent new Initial B Term Commitments
         are provided pursuant to an Initial B Term Commitment Renewal.".

                  12. Section 2.03(c) of the Credit Agreement is hereby amended
by inserting the word "Initial" (i) immediately following the word "Total" and
(ii) immediately preceding the text "C Term Loans-Floating Rate", in each case
appearing in said Section.

                  13. Section 2.03(d) of the Credit Agreement is hereby amended
by deleting said Section in its entirety and inserting the following new Section
2.03(d) in lieu thereof:

                  "(d) The Incremental B Term Commitment of each Lender provided
         pursuant to a particular Incremental Term Loan Commitment Agreement
         shall terminate in its entirety on the respective Incremental B Term
         Borrowing Date for such Incremental Term Loan Commitment Agreement
         (after giving effect to the incurrence of the Incremental B Term Loans
         on each such date).".

                  14. Section 2.03(e) of the Credit Agreement is hereby amended
by deleting said Section in its entirety and inserting the following new Section
2.03(e) in lieu thereof:

                  "(e) The Incremental C Term Commitment of each Lender provided
         pursuant to a particular Incremental Term Loan Commitment Agreement
         shall terminate in its entirety on the respective Incremental C Term
         Borrowing Date for such Incremental Term Loan Commitment Agreement
         (after giving effect to the incurrence of the Incremental C Term Loans
         on each such date).".

                  15. Section 3.01 of the Credit Agreement is hereby amended by
(i) deleting the word "and" immediately prior to the text "(iv)" appearing in
said Section and (ii) inserting the following text at the end of said Section:

                  "; and (v) each prepayment of B Term Loans and C Term
         Loans-Floating Rate pursuant to this Section 3.01 made on or after the
         occurrence of the first Incremental Term Borrowing Date to occur after
         the Sixth Amendment Effective Date and prior to the

                                      -8-
<PAGE>

         second anniversary of such Incremental Term Borrowing Date shall be
         subject to the payment of the fee described in Section 2.01(f)".

                  16. Section 3.02(A)(b)(i) of the Credit Agreement is hereby
amended by (i) deleting the table appearing in said Section in its entirety and
inserting the following new table in lieu thereof:

<TABLE>
<CAPTION>
                  "DATE                         AMOUNT
                   ----                         ------
<S>                                         <C>
                  June 30, 1998             $  171,967.35
                  September 30, 1998        $  171,967.35
                  December 31, 1998         $  171,967.35
                  March 31, 1999            $  171,967.35

                  June 30, 1999             $  171,967.35
                  September 30, 1999        $  171,967.35
                  December 31, 1999         $  171,967.35
                  March 31, 2000            $  171,967.35

                  June 30, 2000             $  171,967.35
                  September 30, 2000        $  171,967.35
                  December 31, 2000         $  171,967.35
                  March 31, 2001            $  171,967.35

                  June 30, 2001             $  171,967.35
                  September 30, 2001        $  171,967.35
                  December 31, 2001         $  171,967.35
                  March 31, 2002            $  171,967.35

                  June 30, 2002             $  171,967.35
                  September 30, 2002        $  171,967.35
                  December 31, 2002         $  171,967.35
                  March 31, 2003            $  171,967.35

                  June 30, 2003             $  171,967.35
                  September 30, 2003        $  171,967.35
                  December 31, 2003         $  171,967.35
                  March 31, 2004            $  171,967.35

                  June 30, 2004             $  171,967.35
                  September 30, 2004        $  171,967.35
                  December 31, 2004         $  10,719,297.50
                  March 31, 2005            $  10,719,297.50

                  June 30, 2005             $  10,719,297.50
                  September 30, 2005        $  10,719,297.50

                                      -9-
<PAGE>

<CAPTION>
                  "DATE                         AMOUNT
                   ----                         ------
<S>                                         <C>
                  December 31, 2005         $  10,719,297.50
                  B Maturity Date           $  10,719,302.10
</TABLE>

and (ii) deleting the proviso appearing at the end of said Section and inserting
the following sentence in lieu thereof:

                  "In the event that the Borrower incurs any Incremental B Term
         Loans pursuant to Section 1.01(e), then (i) each of the foregoing
         Scheduled Repayments occurring after the date of such incurrence
         through and including September 30, 2004 shall be increased by 0.25% of
         the aggregate principal amount of the Incremental B Term Loans so
         incurred and (ii) each of the foregoing Scheduled Repayments occurring
         after September 30, 2004 shall be increased by an amount equal to (x)
         the aggregate principal amount of the Incremental B Term Loans so
         incurred less the portion thereof allocated to the foregoing Scheduled
         Repayments as provided in the preceding clause (i) divided by (y) 6.".

                  17. Section 3.02(A)(b)(ii) is hereby amended by (i) deleting
the table appearing in said Section in its entirety and inserting the following
new table in lieu thereof:

<TABLE>
<CAPTION>
                                       Floating Rate              Fixed Rate
          "Date                           Amount                    Amount
-------------------------           -------------------      -------------------
<S>                                 <C>                      <C>
April 1, 1998                       $   0                    $        313,567
June 30, 1998                       $   58,734               $        301,638
September 30, 1998                  $   58,734               $        307,321
December 31, 1998                   $   58,734               $        330,617
March 31, 1999                      $   58,734               $        336,530

June 30, 1999                       $   58,734               $        342,560
September 30, 1999                  $   58,734               $        348,712
December 31, 1999                   $   58,734               $        363,736
March 31, 2000                      $   58,734               $        370,135

June 30, 2000                       $   58,734               $        376,663
September 30, 2000                  $   58,734               $        383,321
December 31, 2000                   $   58,734               $        402,613
March 31, 2001                      $   58,734               $        409,540

June 30, 2001                       $   58,734               $        416,606
September 30, 2001                  $   58,734               $        515,704
December 31, 2001                   $   58,734               $        529,893
March 31, 2002                      $   58,734               $        539,266

                                      -10-
<PAGE>

<CAPTION>
                                       Floating Rate              Fixed Rate
          "Date                           Amount                    Amount
-------------------------           -------------------      -------------------
<S>                                 <C>                      <C>
June 30, 2002                       $   58,734               $        548,826

September 30, 2002                  $   58,734               $        521,965
December 31, 2002                   $   58,734               $        531,665
March 31, 2003                      $   58,734               $        541,567

June 30, 2003                       $   58,734               $        551,674
September 30, 2003                  $   58,734               $        561,990
December 31, 2003                   $   58,734               $        572,520
March 31, 2004                      $   58,734               $        583,267

June 30, 2004                       $   58,734               $        594,237
September 30, 2004                  $   58,734               $         49,807
December 31, 2004                   $   58,734               $         49,807
March 31, 2005                      $   58,734               $         49,807

June 30, 2005                       $   2,731,131            $      4,970,106
September 30, 2005                  $   2,731,131            $      4,970,106
December 31, 2005                   $   2,731,131            $      4,970,106
March 31, 2006                      $   2,731,131            $      4,970,106

June 30, 2006                       $   2,731,131            $      4,970,106
September 30, 2006                  $   2,731,131            $      4,970,106
December 31, 2006                   $   2,731,131            $      4,970,106
C Maturity Date                     $   2,731,126.82         $      4,970,106".
</TABLE>

and (ii) inserting the following sentence at the end of said Section:

                  "In the event that the Borrower incurs any Incremental C Term
         Loans pursuant to Section 1.01(f), then (i) each of the Scheduled
         Repayments for C Term Loans-Floating Rate occurring after the date of
         such incurrence through and including March 31, 2005 shall be increased
         by 0.25% of the aggregate principal amount of the Incremental C Term
         Loans so incurred and (ii) each of the Scheduled Repayments for C Term
         Loans-Floating Rate occurring after March 31, 2005 shall be increased
         by an amount equal to (x) the aggregate principal amount of the
         Incremental C Term Loans so incurred less the portion thereof allocated
         to the Scheduled Repayments for C Term Loans-Floating Rate as provided
         in the preceding clause (i) divided by (y) 8.".

                  18. Section 5.05(a) of the Credit Agreement is hereby amended
by inserting the text "(other than Incremental B Term Loans and Incremental C
Term Loans)" immediately after the text "all Term Loans" appearing in said
Section.

                                      -11-
<PAGE>

                  19. Section 5.05(c) of the Credit Agreement is hereby amended
by deleting said Section in its entirety and inserting the following new Section
5.05(c) in lieu thereof:

                  "(c) The proceeds of AF Loans may only be used (x) for working
         capital requirements, (y) to finance capital expenditure requirements
         (including Permitted CLEC Expenditures) and Permitted Acquisitions
         and/or (z) to repay RF Loans.".

                  20. Section 5.05 of the Credit Agreement is hereby further
amended by inserting the following new Section 5.05(e) immediately following
Section 5.05(d) thereof:

                  "(e) The proceeds of all Incremental Term Loans shall be
         utilized on the date of incurrence of such Loans for the same purposes
         as AF Loans specified in Section 5.05(c) above."

                  21. Section 7.11(b) of the Credit Agreement is hereby amended
by deleting the table appearing in said Section in its entirety and inserting
the following new table in lieu thereof:

<TABLE>
<CAPTION>
                 "FISCAL QUARTER ENDING                     RATIO
                 ----------------------                     -----
<S>                                                         <C>
                 Trigger Date through                       1.50 to 1.0
                 March 31, 2003

                 June 30, 2003                              1.60 to 1.0
                 through September 31, 2003

                 December 31, 2003                          1.65 to 1.0
                 through March 31, 2004

                 June 30, 2004 through                      1.75 to 1.0
                 December 31, 2004

                 Thereafter                                 2.0 to 1.0
</TABLE>

                  22. Section 7.12(b) of the Credit Agreement is hereby amended
by deleting the table appearing in said Section in its entirety and inserting
the following new table in lieu thereof:

<TABLE>
<CAPTION>
                 "FISCAL QUARTER ENDING                     RATIO
                 ----------------------                     -----
<S>                                                         <C>
                 Trigger Date through                       6.50 to 1.0
                 September 30, 2002

                 December 31, 2002                          6.25 to 1.0

                                      -12-
<PAGE>

                 through March 31, 2003

                 June 30, 2003                              6.00 to 1.0
                 through September 30, 2003

                 December 31, 2003                          5.75 to 1.0
                 through March 31, 2004

                 Thereafter                                 5.50 to 1.0".
</TABLE>

                  23. Section 7.13(b) of the Credit Agreement is hereby amended
by deleting the table appearing in said Section in its entirety and inserting
the following new table in lieu thereof:

<TABLE>
<CAPTION>
                 "FISCAL QUARTER ENDING                     RATIO
                 ----------------------                     -----
<S>                                                         <C>
                  Trigger Date
                  through September 30, 2002                4.00 to 1.0

                  December 31, 2002
                  through September 30, 2003                3.50 to 1.0

                  Thereafter                                3.25 to 1.0".
</TABLE>

                  24. The definition of "Credit Documents" appearing in Section
9 of the Credit Agreement is hereby amended by (i) deleting the word "and"
appearing in said definition and inserting a comma in lieu thereof and (ii)
inserting the text "and each Incremental Term Loan Commitment Agreement"
immediately following the text "Subsidiary Guaranty" appearing in said
definition.

                  25. Section 9 of the Credit Agreement is hereby further
amended by (i) deleting the definitions of "Applicable Base Rate Margin",
"Applicable CC Percentage", "Applicable Eurodollar Margin", "B Term Commitment",
"B Term Commitment Renewal", "B Term Facility", "B Termination Date", "B Term
Loan", "Borrowing", "C Term Commitment", "C Term Facility", "C Term Loan", "C
Term Loans-Floating Rate", "Margin Reduction Discount", "Scheduled Reductions",
and "Total Term Commitment" appearing in said Section and (ii) inserting in the
appropriate alphabetical order the following new definitions:

                  "Applicable Base Rate Margin" shall mean (i) in the case of AF
         Loans and RF Loans, 1.75% LESS the Margin Reduction Discount, if any,
         (ii) in the case of B Term Loans, 2.25% LESS the Margin Reduction
         Discount, if any and (iii) in the case of C Term Loans-Floating Rate,
         2.50% LESS the Margin Reduction Discount, if any; PROVIDED that:

                                      -13-
<PAGE>

                           (I) on each Incremental B Term Borrowing Date, in the
                  event that the "Applicable Base Rate Margin" as set forth in
                  the Incremental Term Loan Commitment Agreement of the
                  Incremental Term Lender(s) providing an Incremental B Term
                  Commitment on such date exceeds the Applicable Base Rate
                  Margin for B Term Loans then in effect under this Agreement
                  (immediately prior to giving effect to such Incremental B Term
                  Borrowing Date but after giving effect to any prior increases
                  thereto (whether pursuant to this clause (I) or clause (II)
                  below)), (x) in the case of B Term Loans, the "Applicable Base
                  Rate Margin" for such Loans as used herein shall be increased
                  on such Incremental B Term Borrowing Date to (and thereafter
                  be, until the same is further increased pursuant to this
                  clause (I) or clause (II) below) the Applicable Base Rate
                  Margin set forth in such Incremental Term Loan Commitment
                  Agreement, and (y) in the case of C Term Loans-Floating Rate,
                  the "Applicable Base Rate Margin" for such Loans as used
                  herein shall be increased on such Incremental B Term Borrowing
                  Date by an amount equal to the remainder of (i) the Applicable
                  Base Rate Margin for B Term Loans on such Incremental B Term
                  Borrowing Date as determined pursuant to preceding subclause
                  (x) LESS (ii) the Applicable Base Rate Margin for B Term Loans
                  as in effect immediately prior to such Incremental B Term
                  Borrowing Date (and the application of this clause (I) on such
                  Incremental B Term Borrowing Date); and

                           (II) on each Incremental C Term Borrowing Date, in
                  the event that the "Applicable Base Rate Margin" as set forth
                  in the Incremental Term Loan Commitment Agreement of the
                  Incremental Term Lender(s) providing an Incremental C Term
                  Commitment on such date exceeds the Applicable Base Rate
                  Margin for C Term Loans-Floating Rate then in effect under
                  this Agreement (immediately prior to giving effect to such
                  Incremental C Term Borrowing Date but after giving effect to
                  any prior increases thereto (whether pursuant to this clause
                  (II) or clause (I) above and including any increase pursuant
                  to clause (I) above on such date as contemplated by the
                  immediately succeeding proviso)), (x) in the case of C Term
                  Loans-Floating Rate, the "Applicable Base Rate Margin" for
                  such Loans as used herein shall be increased on such
                  Incremental C Term Borrowing Date to (and thereafter be, until
                  the same is further increased pursuant to this clause (II) or
                  clause (I) above) the Applicable Base Rate Margin set forth in
                  such Incremental Term Loan Commitment Agreement, and (y) in
                  the case of B Term Loans, the "Applicable Base Rate Margin"
                  for such Loans as used herein shall be increased on such
                  Incremental C Term Borrowing Date by an amount equal to the
                  remainder of (i) the Applicable Base Rate Margin for C Term
                  Loans-Floating Rate on such Incremental C Term Borrowing Date
                  as determined pursuant to preceding subclause (x) LESS (ii)
                  the Applicable Base Rate Margin for C Term Loans-Floating Rate
                  as in effect immediately prior to such Incremental C Term
                  Borrowing Date (and the application of this clause (II) on
                  such Incremental C Term Borrowing Date) (or, in the case of
                  the first Incremental C Term Borrowing Date only, 2.50%);

                                      -14-
<PAGE>

         PROVIDED FURTHER that in the event an Incremental B Term Borrowing Date
         and an Incremental C Term Borrowing Date occur on the same date, for
         purposes of determining the "Applicable Base Rate Margin" for B Term
         Loans and C Term Loans Floating Rate as provided above (and for
         purposes of avoiding any duplicative increases thereto as a result of
         the preceding proviso), (i) clause (I) of the preceding proviso shall
         first be applied as if the respective Incremental B Term Borrowing Date
         had occurred immediately prior to the respective Incremental C Term
         Borrowing Date and (ii) clause (II) of the preceding proviso shall
         thereafter be applied as if the respective Incremental C Term Borrowing
         Date had occurred immediately after such Incremental B Term Borrowing
         Date.

                  "Applicable CC Percentage" shall mean, for any day, a
         percentage equal to (i) in the case of RF Loans, (x) if the unutilized
         portion of the Total Revolving Commitment on such day is less than 50%
         of the Total Revolving Commitment on such day, 0.50% and (y) if the
         unutilized portion of the Total Revolving Commitment on such day equals
         or exceeds 50% of the Total Revolving Commitment on such day, 0.75% and
         (ii) in the case of AF Loans, (x) if the unutilized portion of the
         Total Acquisition Commitment on such day is less than 50% of the Total
         Acquisition Commitment on such day, 0.50% and (y) if the unutilized
         portion of the Total Acquisition Commitment on such day equals or
         exceeds 50% of the Total Acquisition Commitment on such day, 0.75%.

                  "Applicable Eurodollar Margin" shall mean (i) in the case of
         AF Loans and RF Loans, 2.75% LESS the Margin Reduction Discount, if
         any, (ii) in the case of B Term Loans, 3.25% LESS the Margin Reduction
         Discount, if any and (iii) in the case of C Term Loans-Floating Rate,
         3.50% LESS the Margin Reduction Discount, if any; PROVIDED that:

                           (I) on each Incremental B Term Borrowing Date, in the
                  event that the "Applicable Eurodollar Margin" as set forth in
                  the Incremental Term Loan Commitment Agreement of the
                  Incremental Term Lender(s) providing an Incremental B Term
                  Commitment on such date exceeds the Applicable Eurodollar
                  Margin for B Term Loans then in effect under this Agreement
                  (immediately prior to giving effect to such Incremental B Term
                  Borrowing Date but after giving effect to any prior increases
                  thereto (whether pursuant to this clause (I) or clause (II)
                  below)), (x) in the case of B Term Loans, the "Applicable
                  Eurodollar Margin" for such Loans as used herein shall be
                  increased on such Incremental B Term Borrowing Date to (and
                  thereafter be, until the same is further increased pursuant to
                  this clause (I) or clause (II) below) the Applicable
                  Eurodollar Margin set forth in such Incremental Term Loan
                  Commitment Agreement, and (y) in the case of C Term
                  Loans-Floating Rate, the "Applicable Eurodollar Margin" for
                  such Loans as used herein shall be increased on such
                  Incremental B Term Borrowing Date by an amount equal to the
                  remainder of (i) the Applicable Eurodollar Margin for B Term
                  Loans on such Incremental B Term Borrowing Date as determined
                  pursuant to preceding subclause (x) LESS (ii) the Applicable
                  Eurodollar Margin for B Term Loans as in effect immediately
                  prior to such Incremental B Term Borrowing Date

                                      -15-
<PAGE>

                  (and the application of this clause (I) on such Incremental B
                  Term Borrowing Date); and

                           (II) on each Incremental C Term Borrowing Date, in
                  the event that the "Applicable Eurodollar Margin" as set forth
                  in the Incremental Term Loan Commitment Agreement of the
                  Incremental Term Lender(s) providing an Incremental C Term
                  Commitment on such date exceeds the Applicable Eurodollar
                  Margin for C Term Loans-Floating Rate then in effect under
                  this Agreement (immediately prior to giving effect to such
                  Incremental C Term Borrowing Date but after giving effect to
                  any prior increases thereto (whether pursuant to this clause
                  (II) or clause (I) above and including any increase pursuant
                  to clause (I) above on such date as contemplated by the
                  succeeding proviso)), (x) in the case of C Term Loans-Floating
                  Rate, the "Applicable Eurodollar Margin" for such Loans as
                  used herein shall be increased on such Incremental C Term
                  Borrowing Date to (and thereafter be, until the same is
                  further increased pursuant to this clause (II) or clause (I)
                  above) the Applicable Eurodollar Margin set forth in such
                  Incremental Term Loan Commitment Agreement, and (y) in the
                  case of B Term Loans, the "Applicable Eurodollar Margin" for
                  such Loans as used herein shall be increased on such
                  Incremental C Term Borrowing Date by an amount equal to the
                  remainder of (i) the Applicable Eurodollar Margin for C Term
                  Loans-Floating Rate on such Incremental C Term Borrowing Date
                  as determined pursuant to preceding subclause (x) LESS (ii)
                  the Applicable Eurodollar Margin for C Term Loans-Floating
                  Rate as in effect immediately prior to such Incremental C Term
                  Borrowing Date (and the application of this clause (II) on
                  such Incremental C Term Borrowing Date) (or, in the case of
                  the first Incremental C Term Borrowing Date only, 3.50%);

         PROVIDED FURTHER that in the event an Incremental B Term Borrowing Date
         and an Incremental C Term Borrowing Date occur on the same date, for
         purposes of determining the "Applicable Eurodollar Margin" for B Term
         Loans and C Term Loans Floating Rate as provided above (and for
         purposes of avoiding any duplicative increases thereto as a result of
         the preceding proviso), (i) clause (I) of the preceding proviso shall
         first be applied as if the respective Incremental B Term Borrowing Date
         had occurred immediately prior to the respective Incremental C Term
         Borrowing Date and (ii) clause (II) of the preceding proviso shall
         thereafter be applied as if the respective Incremental C Term Borrowing
         Date had occurred immediately after such Incremental B Term Borrowing
         Date.

                  "Borrowing" shall mean the incurrence of Base Rate Loans or
         Eurodollar Loans pursuant to a single Facility by the Borrower from the
         Lenders having Commitments with respect to such Facility on a PRO RATA
         basis on a given date (or resulting from conversions on a given date),
         having in the case of Eurodollar Loans the same Interest Period;
         PROVIDED that (x) Base Rate Loans incurred pursuant to Section 1.10(b)
         shall be considered part of any related Borrowing of Eurodollar Loans
         and (ii) any Incremental B Term Loans or Incremental C Term Loans
         incurred pursuant to Section 1.01(e) or (f), as

                                      -16-
<PAGE>

         the case may be, shall be considered part of the Borrowing of the then
         outstanding B Term Loans or C Term Loans-Floating Rate to which such
         Incremental B Term Loans or Incremental C Term Loans, as the case may
         be, are added to pursuant to Section 1.14(c).

                  "B Term Commitment" of any Lender shall mean the Initial B
         Term Commitment and/or the Incremental B Term Commitment of such
         Lender.

                  "B Term Facility" shall mean and include the Initial B Term
         Facility and the Incremental B Term Facility.

                  "B Term Loans" shall mean and include Initial B Term Loans and
         Incremental B Term Loans.

                  "C Term Commitment" of any Lender shall mean the Initial C
         Term Commitment and/or the Incremental C Term Commitment of such
         Lender.

                  "C Term Facility" shall mean and include the Initial C Term
         Facility and the Incremental C Term Facility.

                  "C Term Loan-Floating Rate" shall mean each Initial C Term
         Loan-Floating Rate and each Incremental C Term Loan.

                  "C Term Loans" shall mean each C Term Loan-Floating Rate and
         each C Term Loan-Fixed Rate.

                  "Incremental B Term Commitment" shall mean, for each
         Incremental Term Lender, the commitment of such Incremental Term Lender
         to make Incremental B Term Loans pursuant to Section 1.01(e) on a given
         Incremental B Term Borrowing Date, as such commitment (x) is set forth
         in the respective Incremental Term Loan Commitment Agreement delivered
         pursuant to Section 1.14(b) and (y) may be terminated pursuant to
         Section 2.03.

                  "Incremental B Term Facility" shall mean the Facility
         evidenced by the Total Incremental B Term Commitment.

                  "Incremental B Term Loan" shall have the meaning provided in
         Section 1.01(e).

                  "Incremental B Term Borrowing Date" shall mean each date on
         which the Borrower incurs a Borrowing of Incremental B Term Loans, each
         of which dates shall be the date of the effectiveness of the respective
         Incremental Term Loan Commitment Agreement pursuant to which such
         Incremental B Term Loans are to be made; PROVIDED that no such date
         shall occur after the Incremental Term Commitment Termination Date.

                  "Incremental C Term Commitment" shall mean, for each
         Incremental Term Lender, the commitment of such Incremental Term Lender
         to make Incremental C Term Loans pursuant to Section 1.01(f) on a given
         Incremental C Term Borrowing Date, as such commitment (x) is set forth
         in the respective Incremental Term Loan Commitment

                                      -17-
<PAGE>

         Agreement delivered pursuant to Section 1.14(b) and (y) may be
         terminated pursuant to Section 2.03.

                  "Incremental C Term Facility" shall mean the Facility
         evidenced by the Total Incremental C Term Commitment.

                  "Incremental C Term Loan" shall have the meaning provided in
         Section 1.01(f).

                  "Incremental C Term Borrowing Date" shall mean each date on
         which the Borrower incurs a Borrowing of Incremental C Term Loans, each
         of which dates shall be the date of effectiveness of the respective
         Incremental Term Loan Commitment Agreement pursuant to which such
         Incremental C Term Loans are to be made; PROVIDED that no such date
         shall occur after the Incremental Term Commitment Termination Date.

                  "Incremental Term Borrowing Date" shall mean and include any
         Incremental B Term Borrowing Date and any Incremental C Term Borrowing
         Date.

                  "Incremental Term Loan" shall mean each Incremental B Term
         Loan and each Incremental C Term Loan.

                  "Incremental Term Commitment" shall mean, for each Incremental
         Term Lender, such Incremental Term Lender's Incremental B Term
         Commitment or Incremental C Term Commitment, as the case may be.

                  "Incremental Term Loan Commitment Agreement" shall mean an
         Incremental Term Loan Commitment Agreement substantially in the form of
         Exhibit L (appropriately completed).

                  "Incremental Term Commitment Termination Date" shall mean
         December 31, 2001.

                  "Incremental Term Lender" shall have the meaning provided in
         Section 1.14(b).

                  "Initial B Term Loan" shall have the meaning provided in
         Section 1.01(a).

                  "Initial B Term Commitment" shall mean, with respect to each
         Lender, the amount set forth opposite such Lender's name on Annex I
         hereto directly below the column entitled "Initial B Term Commitment",
         as the same may be (x) reduced or terminated pursuant to Sections 2.02,
         2.03 and/or 8 or (y) adjusted from time to time as a result of
         assignments to or from such Lender pursuant to Sections 1.13 and/or
         11.04(b) plus the amount, if any, of an Initial B Term Commitment of
         such Lender committed to pursuant to an Initial B Term Commitment
         Renewal.

                  "Initial B Term Commitment Renewal" shall mean the providing
         of additional Initial B Term Commitments from time to time after any
         mandatory repayment of Initial B Term Loans and/or mandatory reduction
         of Initial B Term Commitments pursuant to Section 2.03(b)(iii) or (iv)
         (each, a "B Reduction Event") in an aggregate amount (the

                                      -18-
<PAGE>

         "Additional B Commitment Amount"), selected by the Borrower, not to
         exceed the principal amount of the Initial B Term Loans so repaid and
         the Initial B Term Commitments so reduced, with any Initial B Term
         Commitment Renewal to be effected by: (i) the Borrower requesting in
         writing some or all of the Lenders and/or other Eligible Transferees
         acceptable to the Agents and the Borrower to provide an additional
         Initial B Term Commitment, which request shall be given within 90 days
         following the B Reduction Event but in any event prior to the date
         occurring 255 days after the Closing Date and (ii) each such Lender or
         Eligible Transferee who desires to do so, providing a written notice to
         the Borrower and the Administrative Agent in response to such request
         setting forth the additional Initial B Term Commitment it will offer,
         with the amount so specified (or such lesser amount as is allocated to
         such Lender by the Agents if the aggregate offered additional Initial B
         Term Commitments exceed the Additional B Commitment Amount) to be such
         Person's additional Initial B Term Commitment, it being agreed that any
         such additional Initial B Term Commitments shall terminate on the date
         occurring 270 days after the Closing Date (after giving effect to the
         making of Initial B Term Loans, if any, on such date) and each such
         Person with an additional Initial B Term Commitment shall be a Lender.

                  "Initial B Term Facility" shall mean the Facility evidenced by
         the Total Initial B Term Commitment.

                  "Initial B Termination Date" shall mean the date occurring 270
         days after the Closing Date.

                  "Initial C Term Commitment" shall mean, for each Lender, the
         amount set forth opposite such Lender's name on Annex I hereto directly
         below the column entitled "Initial C Term Commitment," as the same may
         be terminated pursuant to Section 2.03.

                  "Initial C Term Facility" shall mean the Facility evidenced by
         the Total Initial C Term Commitment and the Co-Bank Commitment.

                  "Initial C Term Loan-Floating Rate" shall have the meaning
         provided in Section 1.01(b).

                  "Margin Reduction Discount" shall mean zero, PROVIDED that (I)
         at any time prior to the occurrence of the first Incremental Term
         Borrowing Date to occur after the Sixth Amendment Effective Date, the
         Margin Reduction Discount applicable to B Term Loans and C Term
         Loans-Floating Rate shall be increased to .25% per annum, when, and for
         so long as, the Leverage Ratio as at the end of the then Relevant
         Fiscal Quarter is less than 5.0 to 1 and (II) the Margin Reduction
         Discount applicable to RF Loans and AF Loans (and only such Loans)
         shall be increased to .25%, .50% or .75% per annum, as specified in
         clauses (i), (ii) and (iii) below, as the case may be, when, and for so
         long as, the ratio set forth in such clause has been satisfied as at
         the end of the then Relevant Fiscal Quarter:

                                      -19-
<PAGE>

                  (i) the Margin Reduction Discount for RF Loans and AF Loans
         shall be .25% per annum in the event that as of the end of the Relevant
         Fiscal Quarter the Leverage Ratio is less than 5.50 to 1 but equal to
         or greater than 5.00 to 1;

                  (ii) the Margin Reduction Discount for RF Loans and AF Loans
         shall be .50% per annum in the event that as of the end of the Relevant
         Fiscal Quarter the Leverage Ratio is equal to or greater than 4.50 to 1
         but less than 5.00 to 1; and

                  (iii) the Margin Reduction Discount for RF Loans and AF Loans
         shall be .75% per annum in the event that as of the end of the Relevant
         Fiscal Quarter the Leverage Ratio is less than 4.50 to 1.

                  The Leverage Ratio shall be determined as of the last day of
         the Relevant Fiscal Quarter, by delivery of an officer's certificate of
         the Borrower to the Lenders pursuant to Section 6.01(e), which
         certificate shall set forth the calculation of the Leverage Ratio. The
         Margin Reduction Discount so determined shall apply, except as set
         forth below, from the date on which such officer's certificate is
         delivered to the Administrative Agent to the earlier of (x) the date on
         which the next certificate is delivered to the Administrative Agent
         pursuant to Section 6.01(e) and (y) the 45th day following the end of
         the fiscal quarter in which such first certificate was delivered to the
         Administrative Agent (or the 90th day if such fiscal quarter was the
         last fiscal quarter of a fiscal year). Notwithstanding anything to the
         contrary contained above, the Margin Reduction Discount shall be zero
         (x) if no officer's certificate has been delivered to the Lenders
         pursuant to Section 6.01(e) which sets forth the Leverage Ratio as of
         the last day of the Relevant Fiscal Quarter or the financial statements
         upon which any such calculations are based have not been delivered,
         until such a certificate and/or financial statements are delivered, (y)
         at all times when there shall exist a Default under Section 8.01 or an
         Event of Default and (z) in the case of B Term Loans and C Term
         Loans-Floating Rate only, at all times on and after the first
         Incremental Term Borrowing Date to occur after the Sixth Amendment
         Effective Date. It is understood and agreed that the Margin Reduction
         Discount as provided above shall in no event be cumulative and, in the
         case of the Margin Reduction Discount applicable to RF Loans and AF
         Loans, only the Margin Reduction Discount available pursuant to clause
         (i), (ii) or (iii) of clause (II) of the proviso in the first sentence
         of this definition above, if any, contained in this definition shall be
         applicable.

                  "Sixth Amendment" shall mean the Sixth Amendment to this
         Agreement, dated as of March 30, 2001.

                  "Sixth Amendment Effective Date" shall have the meaning
         provided in the Sixth Amendment.

                  "Scheduled Reduction" shall have the meaning provided in the
         Credit Agreement immediately prior to the Sixth Amendment Effective
         Date.

                                      -20-
<PAGE>

                  "Specified Prepayment Premium Percentage" shall mean, at any
         time, the highest "Voluntary Prepayment Premium Percentage" specified
         in any Incremental Term Loan Commitment Agreement executed and
         delivered on or prior to such time.

                  "Total Incremental B Term Commitment" shall mean the sum of
         the Incremental B Term Commitments of each of the Lenders.

                  "Total Incremental C Term Commitment" shall mean the sum of
         the Incremental C Term Commitments of each of the Lenders.

                  "Total Initial B Term Commitment" shall mean the sum of the
         Initial B Term Commitments of each of the Lenders. "Total Initial C
         Term Commitment" shall mean the sum of the Initial C Term Commitments
         of each of the Lenders.

                  26. Section 11.04(b) of the Credit Agreement is hereby amended
by deleting the text ", with the consent of the Administrative Agent and the
Borrower (which consents shall not be unreasonably withheld)" appearing the last
sentence of said Section and inserting the text ", with prior written notice to
the Administrative Agent," in lieu thereof.

                  27. The Credit Agreement is hereby further amended by adding
new Exhibit L thereto in the form of Exhibit L attached hereto.

II.      AMENDMENTS TO PLEDGE AGREEMENT.

                  1. The Pledge Agreement is hereby amended by deleting the
third recital appearing therein in its entirety.

                  2. Section 1 of the Pledge Agreement is hereby amended by (i)
deleting the text "such Pledgor" in each instance where it appears in clause (i)
of said Section and inserting the text "the Borrower" in lieu thereof, (ii)
deleting the text "such Pledgor" in the first place such text appears in clause
(ii) of said Section and inserting the text "the Borrower" in lieu thereof and
(iii) deleting the text ", including all obligations, if any, of such Pledgor
under its Guaranty (if any) in respect of Secured Interest Rates Agreements"
appearing in clause (ii) of said Section.

                  3. The Pledge Agreement is hereby amended by the following new
Section 26 immediately following Section 25 thereof:

                  "26. At any time a payment is made by any Pledgor (other than
         the Borrower) (each, a "SUBSIDIARY PLEDGOR") in respect of the
         Obligations from the proceeds of any sale or other disposition of
         Collateral owned by such Subsidiary Pledgor (each, a "RELEVANT
         PAYMENT"), the right of contribution of each Subsidiary Pledgor
         hereunder against each other such Subsidiary Pledgor shall be
         determined as provided in the immediately following sentence, with the
         right of contribution of each Subsidiary Pledgor to be revised and
         restated as of each date on which a Relevant Payment is made. At any
         time

                                      -21-
<PAGE>

         that a Relevant Payment is made by a Subsidiary Pledgor that results in
         the aggregate payments made by such Subsidiary Pledgor hereunder in
         respect of the Obligations to and including the date of the Relevant
         Payment exceeding such Subsidiary Pledgor's Contribution Percentage (as
         defined below) of the aggregate payments made by all Subsidiary
         Pledgors hereunder in respect of the Obligations from the proceeds of
         any sale or other disposition of Collateral owned by the Subsidiary
         Pledgors to and including the date of the Relevant Payment (such
         excess, the "AGGREGATE EXCESS AMOUNT"), each such Subsidiary Pledgor
         shall have a right of contribution against each other Subsidiary
         Pledgor who has made (or whose Collateral has been used to make)
         payments hereunder in respect of the Obligations to and including the
         date of the Relevant Payment in an aggregate amount less than such
         other Subsidiary Pledgor's Contribution Percentage of the aggregate
         payments made to and including the date of the Relevant Payment by all
         Subsidiary Pledgors hereunder in respect of the Obligations from the
         proceeds of any sale or other disposition of Collateral owned by the
         Subsidiary Pledgors (the aggregate amount of such deficit, the
         "AGGREGATE DEFICIT AMOUNT") in an amount equal to (x) a fraction the
         numerator of which is the Aggregate Excess Amount of such Subsidiary
         Pledgor and the denominator of which is the Aggregate Excess Amount of
         all Subsidiary Pledgors multiplied by (y) the Aggregate Deficit Amount
         of such other Subsidiary Pledgor. A Subsidiary Pledgor's right of
         contribution pursuant to the preceding sentences shall arise at the
         time of each computation, subject to adjustment to the time of any
         subsequent computation; PROVIDED, that no Subsidiary Pledgor may take
         any action to enforce such right until the Obligations have been paid
         in full and the Total Commitment has been terminated, it being
         expressly recognized and agreed by all parties hereto that any
         Subsidiary Pledgor's right of contribution arising pursuant to this
         Agreement against any other Subsidiary Pledgor shall be expressly
         junior and subordinate to such other Subsidiary Pledgor's obligations
         and liabilities in respect of the Obligations and any other obligations
         owing under this Agreement. As used in this Section 26: (i) each
         Subsidiary Pledgor's "CONTRIBUTION PERCENTAGE" shall mean the
         percentage obtained by dividing (x) the Adjusted Net Worth (as defined
         below) of such Subsidiary Pledgor by (y) the aggregate Adjusted Net
         Worth of all Subsidiary Pledgors; (ii) the "ADJUSTED NET WORTH" of each
         Subsidiary Pledgor shall mean the greater of (x) the Net Worth (as
         defined below) of such Subsidiary Pledgor and (y) zero; and (iii) the
         "NET WORTH" of each Subsidiary Pledgor shall mean the amount by which
         the fair salable value of such Subsidiary Pledgor's assets on the date
         of any Relevant Payment exceeds its existing debts and other
         liabilities (including contingent liabilities, but without giving
         effect to any obligations arising under this Agreement) on such date.
         All parties hereto recognize and agree that, except for any right of
         contribution arising pursuant to this Section 26, each Subsidiary
         Pledgor who makes (or whose Collateral has been used to make) any
         payment in respect of the Obligations shall have no right of
         contribution or subrogation against any other Subsidiary Pledgor in
         respect of such payment. Each of the Subsidiary Pledgors recognizes and
         acknowledges that the rights to contribution arising hereunder shall
         constitute an asset in favor of the party entitled to such
         contribution. In this connection, each Subsidiary Pledgor has the right
         to waive its contribution right against any Subsidiary Pledgor to the
         extent that after giving effect to such waiver such Subsidiary Pledgor
         would remain solvent, in the determination of the Required Lenders.".

                                      -22-
<PAGE>

III.     MISCELLANEOUS PROVISIONS.

                  1. In order to induce the Lenders to enter into this
Amendment, the Borrower hereby represents and warrants that:

                  (a) no Default or Event of Default exists as of the Sixth
         Amendment Effective Date, both before and after giving effect to this
         Amendment; and

                  (b) all of the representations and warranties contained in the
         Credit Agreement or the other Credit Documents are true and correct in
         all material respects on the Sixth Amendment Effective Date, both
         before and after giving effect to this Amendment, with the same effect
         as though such representations and warranties had been made on and as
         of the Sixth Amendment Effective Date (it being understood that any
         representation or warranty made as of a specific date shall be true and
         correct in all material respects as of such specific date).

                  2. This Amendment is limited as specified and shall not
constitute a modification, acceptance or waiver of any other provision of the
Credit Agreement or any other Credit Document.

                  3. This Amendment may be executed in any number of
counterparts and by the different parties hereto on separate counterparts, each
of which counterparts when executed and delivered shall be an original, but all
of which shall together constitute one and the same instrument. A complete set
of counterparts shall be lodged with the Borrower and the Administrative Agent.

                  4. THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE
PARTIES HEREUNDER SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAW
OF THE STATE OF NEW YORK.

                  5. This Amendment shall become effective on the date (the
"Sixth Amendment Effective Date") when each of the following conditions shall
have been satisfied:

                  (i) the Administrative Agent shall have received from each
         Credit Party certified copies of resolutions of the Board of Directors
         of such Credit Party with respect to the matters set forth in this
         Amendment and such resolutions shall be satisfactory to the
         Administrative Agent;

                  (ii) the Administrative Agent shall have received from Paul,
         Hastings, Janofsky & Walker LLP, special New York counsel to the Credit
         Parties, an opinion addressed to the Agents, the Collateral Agent and
         each of the Lenders and dated the Sixth Amendment Effective Date in
         form and substance satisfactory to the Administrative Agent, and
         covering such matters incident to this Amendment as the Administrative
         Agent may reasonably request (including an opinion as to no conflict
         with all Permitted Subordinated Debt and the documentation governing
         the same);

                                      -23-
<PAGE>

                  (iii) the Borrower shall have paid to each Lender which has
         executed and delivered a counterpart of this Amendment on or prior to
         5:00 P.M. (New York time) on Thursday, March 29, 2001, an amendment fee
         equal to the sum of (I) 0.50% of the sum of (x) the Revolving
         Commitment of such Lender as in effect on such date PLUS (y) the
         Acquisition Commitment of such Lender as in effect on such date PLUS
         (II) 0.25% of the aggregate principal amount of the Term Loans made by
         such Lender and outstanding on such date (immediately prior to the
         occurrence of the Sixth Amendment Effective Date);

                  (iv) the Borrower shall have paid to the Administrative Agent
         such fees as may have been agreed to in writing among such parties;

                  (v) the Borrower, each Subsidiary Guarantor, the Required
         AF/RF Lenders, the Required AF Lenders, the Required RF Lenders, the
         Required TF Lenders, the Required B TF Lenders and the Required C TF
         Lenders shall have signed a counterpart hereof (whether the same or
         different counterparts) and shall have delivered (including by way of
         facsimile transmission) the same to the Administrative Agent at its
         Notice Office.

                  6. By executing and delivering a copy hereof, each Credit
Party hereby (x) agrees that all Loans (including, without limitation, upon the
incurrence thereof, the Incremental B Term Loans and Incremental C Term Loans)
shall be fully guaranteed pursuant to the Subsidiary Guaranty in accordance with
the terms and provisions thereof and shall be fully secured pursuant to the
Pledge Agreement and (y) reaffirms all of its obligations and liabilities under
the various Credit Documents to which it is a party.

                  7. From and after the Sixth Amendment Effective Date, all
references in the Credit Agreement and each of the other Credit Documents to the
Credit Agreement and the Pledge Agreement shall be deemed to be references to
the Credit Agreement or the Pledge Agreement, as the case may be, as modified
hereby.

                                      * * *

                                      -24-
<PAGE>

                  IN WITNESS WHEREOF, each of the parties hereto has caused a
counterpart of this Amendment to be duly executed and delivered as of the date
first above written.

                                  FAIRPOINT COMMUNICATIONS, INC.
                                    (f/k/a MJD Communications, Inc.)

                                  By: /s/ Timothy W. Henry
                                     -------------------------------------------
                                     Name: Timothy W. Henry
                                     Title: Vice President of Finance

                                  BANKERS TRUST COMPANY, Individually
                                    and as Administrative Agent

                                  By: /s/ Anca Trifan
                                     -------------------------------------------
                                     Name: Anca Trifan
                                     Title: Director

                                  BANK OF AMERICA, N.A., Individually and
                                    as Syndication Agent

                                  By: /s/ Pamela S. Kurtzman
                                     -------------------------------------------
                                     Name: Pamela S. Kurtzman
                                     Title: Principal

                                  FIRST UNION NATIONAL BANK,
                                    Individually and as Documentation Agent

                                  By: /s/ Franklin M. Wessmock
                                     -------------------------------------------
                                     Name: Franklin M. Wessmock
                                     Title: Sr. Vice President
<PAGE>

                                  COBANK, ACB

                                  By: /s/ Rick Freeman
                                     -------------------------------------------
                                     Name: Rick Freeman
                                     Title: Vice President

                                  MORGAN STANLEY DEAN WITTER
                                    PRIME INCOME TRUST

                                  By:
                                     -------------------------------------------
                                     Name:
                                     Title:

                                  HELLER FINANCIAL, INC.

                                  By: /s/ David R. Compbell
                                     -------------------------------------------
                                     Name: David R. Compbell
                                     Title: Vice President

                                  THE TRAVELERS INSURANCE COMPANY

                                  By: /s/ Allen R. Cantrell
                                     -------------------------------------------
                                     Name: Allen R. Cantrell
                                     Title: Investment Officer

                                  UNION BANK OF CALIFORNIA, N.A.

                                  By: /s/ James C. Opdyke
                                     -------------------------------------------
                                     Name: James C. Opdyke
                                     Title: Assistant Vice President
<PAGE>

                                  CENTURA BANK

                                  By:
                                     -------------------------------------------
                                     Name:
                                     Title:

                                  THE CIT GROUP/EQUIPMENT FINANCING, INC.

                                  By:
                                     -------------------------------------------
                                     Name:
                                     Title:

                                  FLEET NATIONAL BANK

                                  By:
                                     -------------------------------------------
                                     Name:
                                     Title:

                                  DELANO COMPANY
                                    By: Pacific Investment Management
                                    Company as its Investment Advisor

                                  By:
                                     -------------------------------------------
                                     Name:
                                     Title:
<PAGE>

                                  FORTIS CAPITAL CORP. (f/k/a
                                    MEESPIERSON CAPITAL CORP.)

                                  By:
                                     -------------------------------------------
                                     Name:
                                     Title:

                                  By:
                                     -------------------------------------------
                                     Name:
                                     Title:

                                  SENIOR DEBT PORTFOLIO
                                    By: BOSTON MANAGEMENT AND
                                    RESEARCH, as Investment Manger

                                  By: /s/ Payson F. Swaffield
                                     -------------------------------------------
                                     Name: Payson F. Swaffield
                                     Title: Vice President

                                  OXFORD STRATEGIC INCOME FUND
                                    By: Eaton Vance Management as
                                    Investment Advisor

                                  By:
                                     -------------------------------------------
                                     Name:
                                     Title:

                                  GENERAL ELECTRIC CAPITAL
                                    CORPORATION

                                  By: /s/ Karl Kieffer
                                     -------------------------------------------
                                     Name: Karl Kieffer
                                     Title: Duly Authorized Signatory
<PAGE>

                                  FIRSTAR BANK, N.A. (f/k/a MERCANTILE
                                    BANK NATIONAL ASSOCIATION)

                                  By: /s/ Gail F. Scannell
                                     -------------------------------------------
                                     Name: Gail F. Scannell
                                     Title: Vice President

                                  NATIONAL CITY BANK

                                  By: /s/ Elizabeth A. Brosky
                                     -------------------------------------------
                                     Name: Elizabeth A. Brosky
                                     Title: Assistant Vice President

                                  EATON VANCE SENIOR INCOME TRUST
                                    By: Eaton Vance Management as
                                    Investment Advisor

                                  By: /s/ Payson F. Swaffield
                                     -------------------------------------------
                                     Name: Payson F. Swaffield
                                     Title: Vice President

                  Each of the undersigned, each being a Subsidiary Guarantor
under, and as defined in, the Credit Agreement referenced in the foregoing Sixth
Amendment, hereby consents to the entering into of the Sixth Amendment and
agrees to the provisions thereof (including, without limitation, Sections 6 and
7 of Part II thereof).

                                  MJD HOLDINGS CORP.,
                                    as a Subsidiary Guarantor and a Pledgor

                                  By: /s/ Timothy W. Henry
                                     -------------------------------------------
                                     Name: Timothy W. Henry
                                     Title: Vice President of Finance
<PAGE>

                                  MJD VENTURES, INC.,
                                    as a Subsidiary Guarantor and a Pledgor

                                  By: /s/ Timothy W. Henry
                                     -------------------------------------------
                                     Name: Timothy W. Henry
                                     Title: Vice President of Finance

                                  MJD SERVICES CORP.
                                    as a Subsidiary Guarantor and a Pledgor

                                  By: /s/ Timothy W. Henry
                                     -------------------------------------------
                                     Name: Timothy W. Henry
                                     Title: Vice President of Finance

                                  ST ENTERPRISES LTD.
                                    as a Subsidiary Guarantor and a Pledgor

                                  By: /s/ Timothy W. Henry
                                     -------------------------------------------
                                     Name: Timothy W. Henry
                                     Title: Vice President of Finance
<PAGE>

                                  IBM CREDIT CORP.

                                  By: /s/ Thomas S. Curcio
                                     -------------------------------------------
                                     Name: Thomas S. Curcio
                                     Title: Manager of Credit, Commercial &
                                              Special Financing
<PAGE>

                                                                       EXHIBIT L

               FORM OF INCREMENTAL TERM LOAN COMMITMENT AGREEMENT

                            [Names(s) of Lenders(s)]

                                                                          [Date]

FairPoint Communications, Inc.
[Insert Address]

re  INCREMENTAL TERM LOAN COMMITMENT
    --------------------------------

Ladies and Gentlemen:

                  Reference is hereby made to the Credit Agreement, dated as of
March 30, 1998 (as amended, modified or supplemented from time to time, the
"Credit Agreement"), among FairPoint Communications, Inc. (f/k/a MJD
Communications, Inc.) (the "Borrower" or "you"), the lenders from time to time
party thereto (the "Lenders") and Bankers Trust Company, as Administrative Agent
(the "Administrative Agent"). Unless otherwise defined herein, capitalized terms
used herein shall have the respective meanings set forth in the Credit
Agreement.

                  Each Lender (each, an "Incremental Term Lender") party to this
letter agreement (this "Agreement") hereby severally agrees that, subject to the
terms and conditions set forth herein, in Annex I hereto and in the Credit
Agreement, it shall provide the Incremental B Term Commitment and/or the
Incremental C Term Commitment set forth opposite its name on Annex I attached
hereto (for each such Incremental Term Lender, its "Incremental Term
Commitment"). Each Incremental Term Commitment provided pursuant to this
Agreement shall be subject to the terms and conditions set forth in the Credit
Agreement, including Section 1.14 thereof.

                  Each Incremental Term Lender and the Borrower acknowledge and
agree that the Incremental Term Commitments provided pursuant to this Agreement
shall constitute either Incremental B Term Commitments or Incremental C Term
Commitments (as specified in Annex I attached hereto) under, and as defined in,
the Credit Agreement. Each Incremental Term Lender and the Borrower further
agree that (i) the maturity date, interest rate provisions (other than the
interest rate margins which may be as specified on Annex I hereto) and scheduled
amortizations applicable to each Incremental Term Loan to be made available
pursuant to its relevant Incremental Term Commitment provided pursuant to this
Agreement are set forth in the relevant provisions of the Credit Agreement, (ii)
the up-front fees payable in respect of the Incremental Term Commitment(s)
provided by it pursuant to this Agreement shall be as set forth in Annex I to
this Agreement and (iii) the "Applicable Base Rate Margin", the "Applicable
Eurodollar Margin" and the "Voluntary Prepayment Premium Percentage" applicable
to the
<PAGE>

                                                                         Annex L
                                                                          Page 2

respective Incremental Term Loans to be made available pursuant to its
Incremental Term Commitments provided pursuant to this Agreement shall be as set
forth in Annex I to this Agreement (subject, however, to the limitations and
requirements of Section 1.14 of the Credit Agreement)(1).

                  Each Incremental Term Lender party to this Agreement (i)
confirms that it has received a copy of the Credit Agreement and the other
Credit Documents, together with copies of the financial statements referred to
therein and such other documents and information as it has deemed appropriate to
make its own credit analysis and decision to enter into this Agreement and, to
the extent applicable, to become a Lender under the Credit Agreement, (ii)
agrees that it will, independently and without reliance upon the Administrative
Agent or any other Lender and based on such documents and information as it
shall deem appropriate at the time, continue to make its own credit decisions in
taking or not taking action under the Credit Agreement, (iii) appoints and
authorizes the Administrative Agent and the Collateral Agent to take such action
as agent on its behalf and to exercise such powers under the Credit Agreement
and the other Credit Documents as are delegated to the Administrative Agent and
the Collateral Agent, as the case may be, by the terms thereof, together with
such powers as are reasonably incidental thereto, (iv) agrees that it will
perform in accordance with their terms all of the obligations which by the terms
of the Credit Agreement are required to be performed by it as a Lender, and (v)
in the case of each lending institution organized under the laws of a
jurisdiction outside the United States, attaches the applicable forms described
in Section 3.04(b) certifying as to its entitlement to a complete exemption from
United States withholding taxes with respect to all payments to be made under
the Credit Agreement and the other Credit Documents. Upon the execution of a
counterpart of this Agreement by such Incremental Term Lenders, the
Administrative Agent and the Borrower, the delivery to the Administrative Agent
of a fully executed copy (including by way of counterparts and by facsimile)
hereof and the payment of any fees (including, without limitation, the upfront
fees payable pursuant to the immediately preceding paragraph and the
administrative fee payable to the Administrative Agent pursuant to Section
1.14(b)(ii) of the Credit Agreement) required in connection herewith, each
Incremental Term Lender party hereto

----------
(1)      The "Applicable Base Rate Margin" and the "Applicable Eurodollar
         Margin" selected for Incremental B Term Loans and Incremental C Term
         Loans may not be less than the "Applicable Base Rate Margin" and the
         "Applicable Eurodollar Margin" applicable to B Term Loans or C Term
         Loans-Floating Rate, as the case may be, as in effect under the Credit
         Agreement prior to the execution and delivery of this Agreement. In
         addition, the "Voluntary Prepayment Premium Percentage" selected for
         Incremental B Term Loans and Incremental C Term Loans may not be less
         than the "Specified Prepayment Premium Percentage" as in effect under
         the Credit Agreement prior to the execution and delivery of this
         Agreement.
<PAGE>

                                                                         Annex L
                                                                          Page 3

(i) shall be obligated to make the Incremental Term Loans provided to be made by
it as provided in this Agreement on the terms, and subject to the conditions,
set forth in the Credit Agreement, and, to the extent applicable, shall become a
Lender pursuant to the Credit Agreement and (ii) to the extent provided in this
Agreement, shall have the rights and obligations of a Lender thereunder and
under the other Credit Documents.

                  The Borrower acknowledges and agrees that all Obligations with
respect to the Incremental Term Loans to be made available to the Borrower shall
be fully secured pursuant to the Pledge Agreement in accordance with the terms
and provisions thereof. Each Subsidiary Guarantor acknowledges and agrees that
all Obligations with respect to the Incremental Term Loans shall be fully
guaranteed pursuant to the Subsidiary Guaranty in accordance with the terms and
provisions thereof and shall be fully secured pursuant to the Pledge Agreement
in accordance with the terms and provision thereof.

                  This Agreement shall become effective as of the date (the
"Agreement Effective Date") when (i) the Borrower, each Subsidiary Guarantor,
each Incremental Term Lender and the Administrative Agent shall have signed a
counterpart hereof (whether the same or different counterparts) and shall have
delivered (including by way of facsimile transmission) the same to the
Administrative Agent at the Notice Office, (ii) each condition set forth in
Section 1.14 of the Credit Agreement shall have been satisfied and (iii) the
Borrower shall have paid to each Incremental Term Lender the upfront fee set
forth on Annex I.

                  From and after the Agreement Effective Date, all references in
the Credit Agreement and the other Credit Documents to the Credit Agreement
shall be deemed to be references to the Credit Agreement as supplemented hereby.

                  You may accept this Agreement by signing the enclosed copies
in the space provided below, and returning one copy of same to us before the
close of business on __________ __, _____. If you do not so accept this
Agreement by such time, our Incremental Term Commitments set forth in this
Agreement shall be deemed canceled.

                  After the execution and delivery to the Administrative Agent
of a fully executed copy of this Agreement (including by way of counterparts and
by fax) by the parties hereto, this Agreement may only be changed, modified or
varied by written instrument in accordance with the requirements for the
modification of Credit Documents pursuant to Section 11.12 of the Credit
Agreement.
<PAGE>

                                                                         Annex L
                                                                          Page 4

                  THIS AGREEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND
GOVERNED BY THE LAW OF THE STATE OF NEW YORK.

                                          Very truly yours,

                                          [NAMES OF INCREMENTAL TERM LENDERS]

                                          By
                                            --------------------------------
                                            Name:
                                            Title:

Agreed and Accepted
this ___ day of __________, ____:

FAIRPOINT COMMUNICATIONS, INC.
(f/k/a MJD Communications, Inc.)

By:
   --------------------------------
   Name:
   Title:

[NAMES OF SUBSIDIARY GUARANTORS]

By:
   --------------------------------
   Name:
   Title:

Agreed and Accepted by:

BANKERS TRUST COMPANY,
  as Administrative Agent

By:
   --------------------------------
   Name:
   Title:
<PAGE>

                                                                         ANNEX I
                                                                              to
                                                                       EXHIBIT L

                            TERMS AND CONDITIONS FOR
                   INCREMENETAL TERM LOAN COMMITMENT AGREEMENT

1.       Agreement Effective Date:

         __________, ____ (the "Agreement Effective Date")

2.       Commitment Amounts (as of the Agreement Effective Date):

<TABLE>
<CAPTION>
INCREMENTAL TERM LENDER      INCREMENTAL B TERM COMMITMENT       INCREMENTAL C TERM COMMITMENT
<S>                          <C>                                 <C>

----------------             ------------------                  ------------------

Total                        $                                   $
                              -----------------                   -----------------
</TABLE>

3.       UP-FRONT FEE(2):

4.       "APPLICABLE BASE RATE MARGIN":                                        .
                                       ----------------------------------------

5.       "APPLICABLE EURODOLLAR MARGIN":                                       .
                                        ---------------------------------------

6.       "VOLUNTARY PREPAYMENT PREMIUM PERCENTAGE":                            .
                                                   ----------------------------

7.       ADDITIONAL CONDITIONS PRECEDENT FOR PURPOSES OF SECTION 1.14 OF THE
         CREDIT AGREEMENT.(3)

----------

(2)      Insert up-front fees as may be agreed to by the Borrower, the
         Administrative Agent and Incremental Term Lenders.

(3)      Insert any conditions precedent, for purposes of Sections 1.14 of the
         Credit Agreement, to the making of any Incremental Term Loans that are
         required by the Incremental Term Lenders or the Administrative Agent in
         connection with the provision of Incremental Term Commitments pursuant
         to this Agreement. Any officer's certificate required by Section 1.14
         shall be attached hereto.
<PAGE>

                                                                         Annex I
                                                                          Page 2

8.       NOTICE AND INFORMATION:

                  BANKERS TRUST COMPANY
                  One Bankers Trust Plaza
                  130 Liberty Street
                  New York, NY 10006
                  Attn:
                  Telephone:
                  Telecopier:

                  [NAMES OF INCREMENTAL TERM LENDERS]4
                  Address:
                  Attention:
                  Telephone:
                  Telecopier:

----------

(4)      Provide notice information for each Incremental Term Lender to be party
         to this Agreement.Prepared by MERRILL CORPORATION

QuickLinks
 -- Click here to rapidly navigate through this document
EXHIBIT 10.14  

    [*]=Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24d-2 of the Securities Exchange Act of 1934, as amended.  

LICENSE AND RESEARCH AGREEMENT

(Amended and Restated)  

    This License And Research Agreement (the "Agreement") is made and entered into as of September 2, 1999,
(the "Effective Date"), as amended and restated on March 26, 2001 (the "Restatement Date"), by and between Rigel Pharmaceuticals, Inc., a corporation organized under the laws of Delaware
and having a principal place of business at 240 East Grand Avenue, South San Francisco, CA 94080 ("Rigel") and Cell Genesys, Inc., a corporation organized under the laws of Delaware and having
a principal place of business at 342 Lakeside Drive, Foster City, CA 94404 ("CG"). Rigel and CG may be referred to collectively as the "Parties," or individually as a "Party." 

Recitals  

    Whereas, CG controls rights to certain patents relating to [*] cell lines
[*]and [*] cell lines (Rockefeller), and related technology; 

    Whereas, Rigel has a license to the [*] cell lines, associated
vectors and vector libraries under intellectual property rights owned by Stanford University; 

    Whereas, CG and Rigel desire to enter into an agreement granting each other licenses under such patents and other intellectual property
rights as provided herein; 

    Whereas, Rigel is in the business of, among other things, providing services for identifying molecules which bind together in
intracellular signaling pathways, and CG desires that Rigel perform such services for CG to identify peptides, proteins and/or Genetic Material (as defined below) that modulate angiogenesis in
endothelial tissues; 

    Whereas, Rigel wishes to perform additional research in the Field of Research (as defined below) [*]; and 

    Whereas, The Parties wish to confirm CG rights to all Therapeutic Candidates (as defined below) that Rigel identifies in the combined
research program, [*], and CG is willing to waive certain of its rights and to amend and restate this Agreement to [*]; 

    Now THEREFORE, in consideration of the foregoing premises and the covenants and promises contained in this Agreement, the Parties agree
as follows: 

ARTICLE 1

DEFINITIONS  

    1.1 "Affiliate" shall mean, with respect to a Party to this Agreement, any other entity, whether de jure or de facto,
which directly or indirectly controls, is controlled by, or is under common control with, such Party. A business entity or Party shall be regarded as in control of another business entity if it owns,
or directly or indirectly controls, at least fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign entity in a particular jurisdiction) of the voting
stock or other ownership interest of the other entity, or if it directly or indirectly possesses the power to direct or cause the direction of the management and policies of the other entity by any
lawful means whatsoever. 

    1.2 "CG Collaboration Partners" means those third parties which enter into a research or development agreement with CG
under which CG conducts substantial research or development activities in collaboration with such third party and grants a license to such third party under patents and/or know-how owned
or controlled by CG in addition to a sublicense under the Rigel Biological Materials or Rigel Know-How, which licenses and sublicense are for the further development and commercialization
of the results of such collaborative research or development. 

    1.3 "CG [*] Field" means human Gene Therapy and animal Gene Therapy. 

    1.4 "CG Know-How" means all Information Controlled by CG as of the Effective Date that is necessary or
useful for practicing the CG Patents. 

    1.5 "CG License" means the license agreement between CG and Rockefeller University as in effect as of the Effective Date
and attached hereto as Appendix A. 

    1.6 "CG Patents" means the Patents and applications listed on Appendix B, to the extent the same are Controlled
by CG. 

    1.7 "CG Program Field" means the research, development or commercialization of human or animal therapeutic products and
services, which products and/or services are comprised of peptides, proteins or Gene Therapy. 

    1.8 "Control" or "Controlled" means ownership of, or a license to, a particular item, material or intellectual property
right with the ability to grant to the other Party access to and/or a license or sublicense as provided for herein without violating the terms of any agreement with a Third Party under which such
rights were acquired from such Third Party. 

    1.9 "Field of Research" means identification of peptides, proteins and/or Genetic Material that modulate angiogenesis in
endothelial tissues. 

    1.10 "FTE" means a full-time employee or consultant of Rigel or the equivalent thereof. 

    1.11 "FTE Year" means the amount of time one FTE would spend working during one (1) calendar year. 

    1.12 "Gene Therapy" means a product or service for the treatment or prevention of a disease that utilizes  ex vivo or in vivo delivery (via viral or nonviral gene transfer methods or systems) of Genetic
Material, including any cell incorporating Genetic Material. 

    1.13 "Genetic Material" means a nucleotide sequence, including DNA, RNA and complementary and reverse complementary
nucleotide sequences thereto, whether coding or noncoding and whether intact or a fragment. 

    1.14 "Information" means any and all information, including without limitation techniques, inventions, practices,
methods, knowledge, know-how, skill, experience, test data, analytical and quality control data, compositions and assays, and any business, marketing, personnel or financial information or
matters. 

    1.15 [*]  

     1.16 "Patent" means an issued, valid, unexpired patent, including any extension, registration, confirmation, reissue, re-examination
or renewal thereof, or a pending application for a patent, in any country, region or jurisdiction. 

    1.17 "Program Know-How" shall mean any Information developed in the Research relating to the development of
Therapeutic Candidates, excluding Information relating to Targets that are not Therapeutic Candidates. 

    1.18 "Program Patent" shall mean a Patent claiming inventions or discoveries in the Program Know-How. 

    1.19 "Program Technology" shall mean Program Know-How and Program Patents. 

    1.20 "Research" shall have the meaning provided in Section 3.1(a). For purposes of this Agreement,  [* ] 

    1.21 "Research Plan" shall have the meaning provided in Section 3.1(a). 

    1.22 "Rigel Biological Materials" means the [*] cell lines, associated vectors and vector
libraries set forth in Appendix C. 

    1.23 "Rigel Collaboration Partners" means those third parties which enter into a research or development agreement with
Rigel under which Rigel conducts substantial research or development activities in collaboration with such third party and grants a license to such third party under patents and/or
know-how owned or controlled by Rigel in addition to a sublicense under CG Patents and/or CG
Know-How, which licenses and sublicense are for the further development and commercialization of the results of such collaborative research or development. 

    1.24 "Rigel Field" means the creation and use of virally produced peptide and protein libraries for the screening of
transdominant effector peptides and RNA molecules as claimed in the patent applications set forth on Appendix D as well as any processes, techniques and applications disclosed in the foregoing
patent applications; it is understood that the foregoing technology is to be used for (a) the discovery, validation and development of targets for human or animal therapeutics, including
without limitation Targets, and (b) the discovery, testing, development and commercialization of therapeutic, diagnostic and drug delivery products other than Therapeutic Candidates. For the
purposes of this Section 1.23, "disclosed in" shall mean disclosed in the specifications of such patent applications as necessary to practice the invention claimed and not solely as part of the
description of the prior art. 

    1.25 "Rigel Know-How" means all Information Controlled by Rigel as of the Effective Date necessary or useful
for the use or modification of the Rigel Biological Materials. 

    1.26 "Rigel License" means the license agreements between Rigel and Stanford University as in effect as of the Effective
Date and attached hereto as Appendix E. 

    1.27 "RMC" shall have the meaning provided in Section 3.2. 

    1.28 "Screened Genetic Material" shall mean Genetic Material identified via screening against a Target, but which
Genetic Material is not a Therapeutic Candidate. 

    1.29 "Success Criteria" shall have the meaning provided in Section 3.1(b). 

    1.30 "Tail End Period" shall mean the period of six (6) months after the end of the Research Period, the purpose
of which is to permit the RMC to identify Therapeutic Candidates; provided, however, that if this Agreement is terminated prior to or during the Tail End Period, the Tail End Period shall be deemed to
end upon such termination date. 

    1.31 "Target" shall mean a molecule occurring naturally in the body that is shown in the Research [*  ], to directly or indirectly cause or impede angiogenesis in
endothelial tissue, to the extent such molecule (or its binding to another
molecule) is agonized or antagonized by a Therapeutic Candidate. It is understood that a particular protein, peptide or Genetic Material could be both a Therapeutic Candidate and a Target, and in such
case such molecule shall be treated as a "Target" hereunder to the 

extent that such molecule is used as a drug discovery target, and shall at the same time be treated as a "Therapeutic Candidate" hereunder to the extent such molecule is used as a drug or therapy. The
rights of the Parties with respect to Targets that are also Therapeutic Candidates are as set forth in Section 2.4. 

    1.32 "Therapeutic Candidate" shall mean a peptide, protein or Genetic Material discovered, identified, produced or
tested during the Research Period pursuant to the Research  [*], or identified during the Tail End Period, by either Party, which meets the Success Criteria,
and any homologues or derivatives thereof. For such purposes, it is understood that if a protein or peptide meets the Success Criteria, Genetic Material that codes for such protein or peptide (or
homologues or derivatives of such Genetic Material) shall be within the definition of Therapeutic Candidate (and vice-versa). The rights of the Parties with respect to Therapeutic
Candidates that are also Targets are as set forth in Section 2.4. 

    1.33 "[*] Patents" means the patents listed in Appendix F. 

ARTICLE 2

LICENSES  

    2.1 CG License Grants.

    (a) Subject to the terms of the CG License, CG hereby grants to Rigel a royalty-free,
non-exclusive, worldwide license, with the right to sublicense to Rigel Collaboration Partners, under and to CG's right, title and interest in the CG Patents and CG Know-How,
and under and to CG's right, title and interest in any Program Technology owned solely by CG, all for purposes solely within the Rigel Field; and hereby waives any claims against Rigel for the
practice and use of the CG Patents and CG Know-How within the Rigel Field prior to the Effective Date. Any sublicense granted hereunder to Rigel Collaboration Partners shall be limited to
the purposes of such collaboration (as such purposes are described in Section 1.22 above). 

    (b) Subject to Section 2.4 below, CG hereby grants to Rigel: 

    (i)  a royalty-free, exclusive, worldwide license, with the right to grant and authorize sublicenses, under
CG's right, title and interest in the Program Technology that is owned jointly by the Parties under Section 4.1(d) below, and Targets that are similarly owned jointly with Rigel, all to make
and use the Targets for purposes outside the CG Program Field; and 

    (ii) a royalty-free, exclusive, worldwide license, under CG's right, title and interest in the Program
Technology that is owned jointly by the Parties under Section 4.1(d) below, and Targets that are similarly owned jointly with Rigel, all to make and use the Targets as targets for the purposes
of elucidating protein pathways and identifying, researching, developing and/or commercializing proteins, peptides, antibodies, Screened Genetic Material, other biological agents and synthetic organic
molecules that are not themselves Therapeutic Candidates but that [*]. Such license does not extend to the making or use of Targets for the purposes of development and/or
commercialization of Therapeutic Candidates in the CG Program Field. 

It
is understood and agreed that the licenses granted above in this Section 2.1(b) shall specifically exclude the right to make or use any Target or Therapeutic Candidate as a therapeutic agent
or for purposes relating to delivery of a Target or Therapeutic Candidate via Gene Therapy. [*]. Rigel shall retain the right to grant to CG the licenses set forth in
Section 2.2 of this Agreement. [*] 

    (c) CG has entered into a license agreement with the [*] concerning the
[*] Patents which includes the right to sublicense (the "[*] Agreement"); as of the Effective Date, however, the terms under which CG may grant
sublicenses under the [*] Agreement make impractical a sublicense to Rigel under the [*] Patents for purposes of the Rigel Field. In the event that CG
successfully renegotiates the terms of the [*] Agreement such that such sublicense would be practical, CG agrees to discuss in good faith the grant of a sublicense to Rigel
under the [*] 

Patents. The Parties understand and agree, however, that CG is not and shall not be obligated to enter into any agreement with Rigel concerning the [*] Patents, that failure to
reach such an agreement for any reason shall not be deemed a breach of this Agreement and that this Section 2.1(c) shall not be deemed to preclude CG from entering into an agreement with a
third party of any type or at any time concerning the [*] Patents. 

    2.2 Rigel License Grants.  

    (a) Subject to the terms and prior to the termination or expiration of the Rigel License, the Parties agree that Rigel shall grant to CG, at
CG's sole option and upon CG's request, a royalty-free, non-exclusive, worldwide license, without the right to sublicense, under Rigel's right, title and interest in the Rigel
Know-How and Rigel Biological Materials, to make, have made, use, sell, offer for sale and import products in the CG [*] Field. It is understood that in no event
will CG have any obligation to
obtain such license from Rigel. Rigel will give CG thirty (30) days prior written notice of the termination of the Rigel License by Rigel. 

    (b) Rigel hereby grants to CG: 

    (i)  subject to Section 2.1(b) above, (y) a royalty-free, exclusive, worldwide license, with
the right to grant and authorize sublicenses, under Rigel's right, title and interest in the Program Technology (including without limitation the Therapeutic Candidates) owned solely by Rigel or
jointly with CG, to make, have made, use, sell, offer for sale and import products, and otherwise exploit the Program Technology, in each case for purposes solely within the CG Program Field, and
(z) a royalty-free, exclusive, worldwide license, with the right to grant and authorize sublicenses, under any Information and intellectual property created by Rigel
[*], to make, have made, use, sell, offer for sale and import Therapeutic Candidates within the CG Program Field; and 

    (ii) subject to rights previously granted to third parties, a royalty-free, non-exclusive,
worldwide license, with the right to grant sublicenses, under Rigel's right, title and interest in and to all Patents with priority dates prior to the Effective Date that claim Therapeutic Candidates,
or the manufacture or use thereof, to make, have made, use and sell products in Gene Therapy incorporating such Therapeutic Candidates. 

    (c) In addition, Rigel hereby grants to CG (i) a royalty-free, non-exclusive license,
with the right to sublicense to CG Collaboration Partners, under Rigel's right, title and interest in the Targets to make and use the Targets solely for the research and development of the Therapeutic
Candidates in the Field of Research, and (ii) a royalty-free, non-exclusive license, with the right to sublicense to CG Collaboration Partners, under any Information and
intellectual property created by Rigel [*], to make and use the Targets solely for the research and development of the Therapeutic Candidates in the Field of Research. For
clarity, it is understood and agreed that the licenses granted to CG under this Section 2.2 specifically exclude the performance by CG of research on or with a Target which is outside the Field
of Research. Any sublicense granted hereunder to CG Collaboration Partners shall be limited to the purposes of such collaboration. 

    2.3 Rigel Covenant. Rigel hereby covenants that neither Rigel nor its Affiliates will make any claims against CG, its
permitted sublicensees, distributors and customers in the chain of title with CG or its permitted sublicensees for Patent infringement as a result of activities which are explicitly permitted under
the terms of this Agreement, nor shall Rigel or its Affiliates authorize a third party to make such a claim, and Rigel agrees to cooperate with CG in the defense against any such claim by licensees of
Rigel. 

    2.4 Molecules That Are Both Targets and Therapeutic Candidates. With respect to each particular protein, peptide or
Genetic Material that is both a Target and a Therapeutic Candidate (each a "Dual Molecule"), the parties agree that (i): CG shall have (y) the exclusive right to research, develop, make, have
made, use, sell, offer for sale and import such Dual Molecule (including homologues and
derivatives of such Genetic Material) as a therapeutic agent or such Dual Molecule (including homologues and derivatives of such Genetic Material) for Gene Therapy, and (z) to make and use such 

Dual Molecule in accordance with Sections 2.2(b) and (c); and (ii) Rigel shall have the exclusive right to research, develop, make, have made and use such Dual Molecule for the purposes set
forth in Section 2.1(b)(i); and (iii) Rigel shall have the exclusive right to research, develop, make, have made and use such Dual Molecule for the purposes set forth in
Section 2.1(b)(ii). For the sake of clarity, CG's exclusive rights as described in this Section 2.4 shall not be construed to exclude Rigel or its permitted licensees from making and
using such molecule as a target in research to elucidate protein pathways in which such Dual Molecule is involved, or to discover, generate, develop and commercialize proteins, peptides, antibodies,
Screened Genetic Material, other biological agents and synthetic organic molecules that may or may not modulate the activity of such Target or pathways but are not themselves Therapeutic Candidates.
All activities of Rigel with respect to the use of Targets shall remain subject to the provisions of Section 3.5. 

    2.5 No Other License. No right or license is granted by either Party to the other under any other intellectual property
other than those items expressly included in the licenses granted in this Article 2. Accordingly, no license shall be deemed granted by implication, estoppel or otherwise, if such license is
not expressly and specifically granted in this Article 2. 

ARTICLE 3

RESEARCH  

    3.1 Research.  

    (a) Rigel agrees to (i) use diligent efforts to conduct research within the Field of Research (the "Research"), in accordance with the
research plan (the "Research Plan") incorporated hereby in, and appended to, this Agreement as Appendix G, as amended from time to time by written agreement of the Parties; and (ii) use
diligent efforts to meet the goals of the Research Plan according to the timetables set forth therein. Without limiting the foregoing, the Research shall commence on the Effective Date and terminate
upon the earlier of three (3) years after the Effective Date or the termination of the Agreement (the "Research Period"). Rigel will commit [*] during each year of the
Research Period, or such other allocation as the RMC may decide, provided that in the event the RMC decides to reallocate FTEs between years, Rigel shall have no obligation to commit more than
[*] in total over the entire Research Period. It is understood and agreed that the scope of CG's licenses under Section 2.2 shall not be limited by (x) the number
of FTEs performing the Research, (y) whether such FTEs are performing research in accordance with the Research Plan [*]. The individual FTEs who
will initially conduct the Research are listed in Appendix H and may be replaced by Rigel, as reasonably agreed by the Parties, with other FTEs of comparable skill and expertise. Rigel agrees
to test against the Success Criteria during the Research Period any proteins, peptides and Genetic Material produced or evaluated in connection with the Research as contemplated in the Research Plan. 

    (b) The Parties shall reasonably establish criteria for determining whether a particular peptide, protein or Genetic
Material modulates angiogenesis in endothelial tissue in assays performed at Rigel, as such criteria are contemplated in the Research Plan (the "Success Criteria"). 

    3.2 Research Management Committee. The Parties shall form a research management committee (the "RMC") comprised
of four (4) individuals, two (2) being Rigel employees appointed and replaced by Rigel at its discretion, and two (2) being CG employees appointed and replaced by CG at its
discretion. The size and composition of the RMC may be modified by mutual agreement of the Parties. The RMC shall evaluate the results of the Research set forth in the research reports pursuant to
Section 3.4(a) to assess whether a peptide, protein or Genetic Material is a Therapeutic Candidate, and perform such other duties as specifically delegated to the RMC by mutual written
agreement of the Parties. 

    3.3 RMC Meetings and Actions. RMC meetings shall take place at such times and places as shall be determined by the RMC
in order for the RMC to fulfill its obligations under Section 3.2. It is 

expected that the meetings will alternate between appropriate offices of each Party, or at such other convenient locations as agreed. If agreed by its members, the RMC may conduct meetings by
telephone or video conference or other acceptable electronic means, provided that any decisions made during such meeting are recorded in writing and confirmed by signature of at least one
(1) of the RMC members from each of the Parties. All decisions of or actions taken by the RMC shall be by unanimous approval of all the members of the RMC, and voting on any matters shall be
reflected in the minutes of the meeting at which the vote was taken. If the RMC is unable to reach unanimous decision on any particular matter or issue, such matter or issue shall be referred to the
chief executive officer of each Party or their designees for resolution. It is understood that, for purposes of determining the Parties' rights and obligations under this Agreement, the authority of
the RMC shall be limited to deciding those specific issues specifically delegated to the RMC in other Articles of this Agreement (i.e., other than the general matters described in this
Article 3). 

    3.4 Reports; Disclosure.  

     (a) Rigel shall keep CG fully informed of the progress and results of the Research (including the discovery of Targets and/or Therapeutic
Candidates [*]) and shall provide written reports at or before each RMC meeting describing its activities, the level of effort applied to, and the results of, the Research,
specifically including Rigel's determination as to which peptides, proteins or Genetic Material
as of the date of such report meet the Success Criteria. Such RMC reports shall be in such form and contain such detail as the RMC shall determine. Rigel agrees to fully disclose to CG the Program
Technology and the Targets, and to provide CG with reasonable quantities of Targets and Therapeutic Candidates generated or utilized in connection with the Research. 

    (b) Rigel agrees to maintain records of its activities in performing the Research, in good scientific manner, and to
permit CG to have access to such records upon ten (10) days written notice to Rigel and during regular business hours, to the extent reasonably necessary to verify that Rigel has met its
obligations under this Section 3.4. 

    3.5 Exclusivity of Efforts. Except as explicitly set forth in this Section 3.5, Rigel agrees that neither Rigel
nor any of its Affiliates shall directly or indirectly conduct or sponsor any research, develop or otherwise commercialize any products or technologies within the Field of Research, other than
pursuant to the Research Plan, during the Research Period and for a period of one (1) year following the Research Period. Without limiting the foregoing, Rigel shall not appoint or license any
third party to develop, market, sell or otherwise distribute such products until after the expiration of one (1) year following the Research Period. [*  ] 

ARTICLE 4

INTELLECTUAL PROPERTY MATTERS  

    4.1 Ownership and Prosecution. Subject to the terms of this Agreement, as between the Parties hereto: 

    (a) It is understood that CG retains its entire right, title and interest in the CG Patents and CG Know-How,
subject only to the rights expressly granted to Rigel hereunder, and shall have the right, but not the obligation, to file, prosecute and maintain any Patents related thereto at its expense. 

    (b) It is understood that Rigel retains its entire right, title and interest in the Rigel Biological Materials and Rigel
Know-How, subject only to the rights expressly granted to CG hereunder, and shall have the right, but not the obligation, to file, prosecute and maintain any Patents related thereto at its
expense. 

    (c) It is understood that, subject only to the rights expressly granted to the other Party hereunder, each Party retains
its entire right, title and interest in and to any inventions, discoveries, know-how, trade secrets, and other information made or developed solely by such Party and/or its consultants in
the course of the performance of this Agreement ("Sole Inventions"), and, subject to subsection (e) below, shall have the right, but not the obligation, to 

file, prosecute and maintain any Patents claiming its Sole Inventions ("Sole Patents") in all countries of the world. 

    (d) Both Parties shall jointly own any inventions, discoveries, know-how, trade secrets, and other
information, that are made jointly by the Parties in the course of the performance of this Agreement ("Joint Inventions"). Subject to subsection (e) below, the RMC shall designate the Party
which shall be responsible for filing, prosecuting and maintaining Patents claiming Joint Inventions ("Joint Patents"). All costs and expenses of filing, prosecuting and maintaining such Joint Patents
will be borne equally by the Parties. The Party designated by the RMC to perform patenting activities shall seek the comments of the other Party and shall keep the other informed of the progress of
such prosecution by providing quarterly status reports and copies of all correspondence between their patent counsel and the patent offices of the countries where such applications were filed. Such
other Party shall reasonably assist the Party designated by the RMC in the prosecution of Joint Patents, including, without limitation, by executing any necessary powers of attorney. Subject to the
rights and licenses granted to the other Party in Section 2.1(b) and 2.2(b), it is understood that neither Party shall have any obligation to account to the other, or obtain the consent of the
owner, with respect to the commercialization, licensing or enforcement of any Joint Inventions or Joint Patents, and hereby waives any right it may have under the laws of any country to require such
accounting or consent. 

    (e) CG shall have the right but not the obligation (either itself or through its designee) to file, prosecute and
maintain Patents claiming Therapeutic Candidates ("Candidate Patents"); provided, however, that for any molecule that is a Therapeutic Candidate and a Target: (i) CG shall have the right but
not the obligation (either itself or through its designee) to file, prosecute and maintain Patents claiming uses of such molecule in the CG Program Field and such Patents also shall be Candidate
Patents; and (ii) Rigel shall have the right, but not the obligation, to file, prosecute and maintain any Patents claiming the composition of matter of such molecule or claiming any use of the
molecule outside the CG Program Field or in the Rigel Field. All costs and expenses of filing, prosecuting and maintaining Candidate Patents will be borne by the Party that undertakes such
prosecution. The Party undertaking such prosecution shall seek the comments of the other Party and shall keep the other Party informed of the progress of such prosecution by providing quarterly status
reports and copies of all correspondence between their patent counsel and the patent offices of the countries where such applications were filed. Each Party shall reasonably assist the other Party in
the prosecution of Candidate Patents, including, without limitation, by executing any necessary powers of attorney and other documents necessary for such prosecution. 

    (f)  Each Party agrees to keep the other Party fully informed as to prosecution and maintenance (including without
limitation any interference, opposition or other prosecution or other proceedings) with respect to patents claiming and disclosing subject matter within the Program Technology. In the event that a
Party elects not to prosecute or maintain any patent rights in a Sole Invention comprising Program Technology, it shall promptly notify the other Party and authorize the other Party to seek or
continue such prosecution and maintenance at such other Party's expense. In such case the owner of such Sole Invention shall cooperate fully with the other Party to facilitate such prosecution and
maintenance. 

    4.2 Infringement and Similar Actions. As between the Parties hereto: 

    (a) CG shall have the sole and exclusive right, at its expense, to prosecute any and all infringement or wrongful use of
the CG Patents and CG Know-How, and (subject to paragraph (c) below) Sole Patents owned by CG and/or to enter settlements, judgments or other arrangements respecting such
infringement or wrongful use. CG may retain all damages and other amounts recovered as a result of any such action, settlement, judgment or other arrangement. 

    (b) Rigel shall have the sole and exclusive right, at its expense, to prosecute any and all infringement or wrongful use
of the Rigel Know-How, the Rigel Biological Materials, and (subject to paragraph (c) below) Sole Patents owned by Rigel and/or to enter settlements, judgments or 

other arrangements respecting such infringement or wrongful use. Rigel may retain all damages and other amounts recovered as a result of any such action, settlement, judgment or other arrangement. 

    (c) With respect to infringement of any Program Patents in the CG Program Field, CG shall have the right, but not the
obligation, (directly or through designees) to institute, prosecute and control at its own expense and for its own benefit, any action or proceeding with respect to such infringement. With respect to
other infringement of any Program Patents (i.e., outside the CG Program Field), Rigel shall have the right, but not the obligation, (directly or through designees) to institute, prosecute and control,
at its own expense and for its own benefit, any action or proceeding with respect to such infringement. If a Party with the right to do so fails to bring an action or proceeding against a suspected
infringer within a reasonable period after receiving a written request by the other Party to do so, such other Party shall have the right to bring and control an action against such infringer by
counsel of its own choice and retain for its own account any amounts recovered from third parties. If one Party brings any such action or proceeding, the other Party agrees to be joined as a Party
plaintiff if necessary to prosecute the action and to give the first Party reasonable assistance and authority to file and prosecute the suit. 

    (d) Each Party shall promptly notify the other in writing of any alleged or threatened infringement of Joint Patents of
which it becomes aware and which may adversely impact the rights of the Parties hereunder. Promptly upon such notification, the Parties shall meet to discuss the strategy and appropriate steps to be
taken to deal with such infringement. Any recovery obtained by settlement or otherwise shall be disbursed as follows: first, any reasonable expenses incurred in connection with such action (including
counsel fees) by both Parties are reimbursed; thereafter, the net recovery shall be shared between the Parties according to the ratio of their respective contributions to the litigation costs. This
paragraph shall not be deemed to limit the Parties' respective rights to enforce Joint Patents, or to limit the rights granted under paragraph (c) above. 

    4.3 Third Party Claims.

    (a) Except to the extent expressly warranted in Article 7, and subject to the indemnification obligation in
Article 5, CG shall have no liability to Rigel with respect to any claim, suit or action alleging that the practice of the license rights granted by CG under Section 2.1 infringes any
intellectual property or other right of a third party. Except to the extent expressly warranted in Article 7, and subject to the indemnification obligation in Article 5, Rigel shall have
no liability to CG or its Affiliates with respect to any claim, suit or action alleging that the practice of the license rights granted under Section 2.2 infringes any intellectual property or
other rights of a third party. 

    (b) Rigel hereby agrees to provide reasonable assistance to CG, at its request, in defending any action or claim
initiated by a third party against CG arising from any claim that the use or practice of the Rigel Know-How, Rigel Biological Materials or the Target by CG or its Affiliates infringes that
third party's proprietary rights. CG hereby agrees to provide Rigel reasonable assistance, at its request and expense, in defending any action or claim initiated by a third party against Rigel or its
Affiliates arising from any claim that the use or practice of the CG Patents or CG Know-How by Rigel or its Affiliates infringes that third party's proprietary rights. 

    (c) If a third party asserts against CG that a patent, trademark or other intangible right owned by it is infringed by
any product in the CG Program Field derived or resulting from or incorporating Program Technology, CG will be solely responsible for defending against any such assertions at its cost and expense. Each
Party will give prompt written notice to the other of any such claim. Rigel will assist in the defense of any such claim as reasonably requested by CG, at CG's expense, and may retain separate counsel
at its own expense at any time. 

    (d) Neither Party shall enter into any settlement of any claim which would admit the invalidity of Patents within the
Program Technology without the other Party's prior written consent, which consent shall not be unreasonably withheld or delayed. 

    4.4 Pass-Through Royalties. In consideration for the licenses granted herein: 

    (a) Rigel agrees to pay any amounts which CG is required to pay to Rockefeller University under the CG License as a
result of CG's grant to Rigel of license rights to CG Patents or CG Know-How to Rigel or the exercise of the license rights granted by CG under the CG License. 

    (b) Rigel agrees to pay CG (i) [*] for the license granted to Rigel hereunder to the CG
Patents related to the [*] cell lines, and (ii) [*] for each sublicense granted by Rigel under this Agreement. 

    (c) CG agrees that in the event CG exercises its option to obtain a license pursuant to Section 2.2(a) above, CG
will pay any amounts which Rigel is required to pay to Stanford University under the Rigel License as a result of Rigel's grant to CG of license rights to Rigel Biological Materials or Rigel
Know-How to CG or the exercise of the license rights granted by Rigel under the Rigel License. It is understood that unless and until CG obtains such license rights from Rigel, CG shall
not be obligated to pay to Rigel or to Stanford University any amounts that Rigel is required to pay to Stanford University under the Rigel License. 

ARTICLE 5

INDEMNIFICATION  

    5.1 CG Indemnity. CG agrees to indemnify, hold harmless and defend Rigel, its Affiliates, agents and employees from and
against any and all liabilities, losses, damages, costs, fees and expenses, including reasonable legal expenses and attorneys' fees (collectively, "Losses") arising out of suits, claims, actions, or
demands, brought or made by a third party ("Third Party Claim") against Rigel, its Affiliates, agents and employees, based on (i) CG's use and practice of the Rigel Know-How, Rigel
Biological Materials, the Program Technology or the Targets, or (ii) breach of CG's warranties under Article 7 below, or (iii) the manufacture, use, handling, storage, sale or
other disposition of Rigel Biological Materials, Program Technology, the Targets or any products resulting or derived from the Rigel Biological Materials or the Program Technology by CG, its
Affiliates, agents, employees or sublicensees, all except to the extent such Losses or Third Party Claims result from the negligence or willful misconduct of Rigel or a breach of Rigel's warranties
under Article 7 below. 

    5.2 Rigel Indemnity. Rigel agrees to indemnify, hold harmless and defend CG, its Affiliates, agents and employees from
and against any and all Losses arising out of any Third Party Claims against CG, its Affiliates, agents and employees based on (i) Rigel's use or practice of the CG Patents the CG
Know-How or the Program Technology, (ii) breach of Rigel's warranties under Article 7 below, or (iii) the manufacture, use, handling, storage, sale or other
disposition of Program Technology, the Targets or any products resulting or derived from the Program Technology by Rigel, its Affiliates, agents, employees or sublicensees, all except to the extent
such Losses or Third Party Claims result from the negligence or willful misconduct of CG, or a breach of CG's warranties under Article 7 below. 

    5.3 In the event that a Party is seeking indemnification under this Article 5, it shall inform the other Party of
a claim or suit as soon as reasonably practicable after it receives notice of the claim or suit, shall permit the indemnifying Party to assume direction and control of the defense of the claim or suit
(including the right to settle the claim or suit solely for monetary consideration), and shall cooperate as
reasonably requested (at the expense of the indemnifying Party) in the defense of the claim or suit. Neither Party will enter into any settlement or claim pursuant to this Section 5.3 which is
materially adverse to the rights of the other Party herein, without the other Party's prior written consent, which will not be unreasonably withheld or delayed. 

ARTICLE 6

CONFIDENTIALITY  

    6.1 Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the
Parties agree that, for the term of this Agreement and for five (5) years thereafter, the Party receiving any Information or materials furnished to it by the other Party pursuant 

to this Agreement (collectively, "Confidential Information") shall keep confidential and shall not publish or otherwise disclose or use such Confidential Information for any purpose other than as
provided for in this Agreement. 

    6.2 Exceptions. The obligations in Section 6.1 shall not apply to any Information or materials to the extent that
the receiving Party can establish by competent proof that such Information or materials: 

    (a) was already known to the receiving Party, other than under an obligation of confidentiality, at the time of
disclosure by the other Party; 

    (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the
receiving Party; 

    (c) became generally available to the public or otherwise part of the public domain after its disclosure and other than
through any act or omission of the receiving Party in breach of this Agreement; or 

    (d) was disclosed to the receiving Party, other than under an obligation of confidentiality, by a Third Party who had no
obligation to the disclosing Party not to disclose such information to others. 

    6.3 Authorized Disclosure. Each Party may disclose the other's Confidential Information to the extent such disclosure is
reasonably necessary (i) to exercise the rights granted to such Party hereunder (including the right to grant sublicenses as permitted by this Agreement provided that prior to any disclosure to
a sublicensee, such sublicensee has executed a confidentiality agreement with terms corresponding to this Article 6); and (ii) to file or prosecute patent applications, to prosecute or
defend litigation, to comply with applicable governmental regulations or to conduct preclinical or clinical trials; provided that if a Party is required by law or regulation to make any such
disclosure of the other Party's Confidential Information it will, except where impracticable for necessary disclosures, for example in the event of medical emergency, give reasonable advance notice to
the other Party of such disclosure requirement and, except to the extent inappropriate in the case of patent applications, will use its best efforts to secure confidential treatment of such
Confidential Information required to be disclosed. 

    6.4 Survival. This Article 6 shall survive the termination or expiration of this Agreement for a period of five
(5) years. 

ARTICLE 7

WARRANTY MATTERS  

    7.1 Limited Warranties. CG hereby represents and warrants to Rigel that CG has the full right and power to grant the
licenses granted to Rigel under Section 2.1(a). Rigel hereby represents and warrants to CG that Rigel has the full right and power to grant the licenses granted to CG under Section 2.2. 

    7.2 General Warranties. Each of the Parties hereby represents and warrants to the other that (i) it is a
corporation duly organized and validly existing in good standing under the laws of its state of incorporation, (ii) it is duly qualified and authorized to enter into and perform its obligations
under this Agreement, (iii) it has full power, authority and legal right to enter into and perform this Agreement, and (iv) the execution, delivery, and performance of this Agreement has
been duly authorized by all necessary corporate action on the part of each Party and does not contravene any law binding on it, its Articles of Incorporation or Bylaws, any indenture, mortgage,
contract or other agreement to which it is a Party or by which it is bound or any laws, governmental rule, regulation or order. 

    7.3 Intellectual Property Warranties.

    (a) Each of the Parties hereby represents and warrants to the other that (i) it does not Control any Patents that
would dominate the Patents licensed to the other Party hereunder, (ii) it 

is not aware of any claims of a third party which would call into question the rights of such Party in the licensed subject matter or its right to grant the licenses granted to the other Party
hereunder, (iii) it has provided the other Party with all information concerning royalty obligations pertinent to the licenses granted to the other Party hereunder; and (iv) it will use
commercially reasonable efforts to keep in force any license agreement from which the license or sublicense granted to the other Party under this Agreement is derived to the extent that such license
agreement does not provide for a survival of any sublicenses granted by such Party. 

    (b) Rigel further warrants to CG that as of the Effective Date (i) to the best of its knowledge, Rigel's conduct
of the Research, and the manufacture, sale and use of Therapeutic Candidates will not infringe any third party intellectual property rights, and without limiting the foregoing, Rigel warrants that
Rigel's conduct of the Research will not infringe any of the patents listed in Appendix I hereto; (ii) Rigel does not know of any third party other than Stanford University having a
claim in the Rigel Biological Materials; and (iii) Rigel has the right to grant to CG a license under the Rigel Biological Materials and the Rigel Know-How to make, use and sell
products in the CG [*] Field. 

    (c) CG further warrants to Rigel that CG has the right to grant to Rigel a license under the CG Patents and CG
Know-How to make, use and sell products within the Rigel Field. 

    (d) Rigel warrants that it has not as of the Effective Date entered into an agreement with any third party licensing or
granting rights to Rigel technology in the Field of Research. 

    7.4 Limitation on Warranties. EXCEPT AS PROVIDED IN SECTIONS 7.1, 7.2, AND 7.3 ABOVE, NEITHER PARTY MAKES ANY WARRANTIES
TO THE OTHER PARTY, WHETHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE AS TO ANY PRODUCT OR PROCESS, OR AS TO THE VALIDITY OR
SCOPE OF ANY PATENTS, OR THAT ANY LICENSED BIOLOGICAL MATERIALS, PATENTS OR KNOW-HOW WILL BE FREE FROM INFRINGEMENT OF PATENTS OF ANY THIRD PARTY, OR THAT NO THIRD PARTIES ARE INFRINGING
SAME. 

ARTICLE 8

TERM AND TERMINATION  

    8.1 Term of Agreement. Unless earlier terminated as otherwise provided in this Article 8, this Agreement shall
remain in effect until the expiration of the last to expire of the CG Patents or Program Patents. 

    8.2 Termination for Breach. A Party may terminate this Agreement prior to the expiration of the Agreement in the event
that the other Party is in breach of or default under a material term of the Agreement, and the breaching Party does not cure such breach or default within thirty (30) days of written notice
thereof from the non-breaching Party. Subject to Section 8.3 below, upon any such termination, all the licenses granted by and between the Parties herein shall terminate; provided
that any sublicense granted by a Party hereunder to a third party prior to such termination shall survive such termination, so long as the sublicensee agrees to be bound by the applicable terms of
this Agreement. 

    8.3 Survival. Upon expiration or termination of this Agreement, the rights and obligations under Articles 5 and 6 and
Sections 7.4, 8.3, 9.2, 9.3, 9.7 and 9.10 shall continue. In addition, upon expiration or termination of this Agreement after the end of the Research Period, the licenses granted under
Article 2 above and the rights and obligations under Article 4 shall survive. Further, subject to Sections 2.1(b) and 2.2(b) if they survive the termination or expiration of this
Agreement as provided above, neither Party shall have any obligation to account to the other, or obtain the consent of the owner, with respect to the commercialization, licensing or enforcement of any
Joint Patents, and hereby waives any right it may have under the laws of any country to require such accounting or consent. 

ARTICLE 9

MISCELLANEOUS  

    9.1 Relationship of the Parties. This Agreement creates only licensor-licensee and sublicensor-sublicensee relationships
between Rigel and CG. No partnership or other legal relationship is created hereunder. Neither Party is, or will be deemed to be, an agent or legal representative of the other Party for any purpose.
Neither Party will be entitled to enter into any contracts in the name of or on behalf of the other Party, and neither Party will be entitled to pledge the credit of the other Party in any way or hold
itself out as having authority to do so. 

    9.2 Assignment. This Agreement may not be assigned by either Party without the prior written consent of the other Party,
which consent shall not be unreasonably withheld; provided, however, that a Party may assign this Agreement without such consent to any Affiliate or to a successor in interest by way of merger,
acquisition, sale or transfer of substantially all of its business or assets pertaining to the subject matter of this Agreement. The Agreement will be binding upon and inure to the benefit of all
permitted successors and assignees of the Parties hereunder, and the name of each Party appearing herein will be deemed to include the names of such Party's successors and assignees. 

    9.3 Use of Names. No Party hereto may use the name of the other Party in public announcements without the prior consent
of the other Party as required by law or regulation. 

    9.4 Amendment. No amendment, modification or supplement of any provision of the Agreement will be valid or effective
unless made in writing and signed by a duly authorized officer of each Party. 

    9.5 Waiver. No provision of the Agreement will be waived by any act, omission or knowledge of a Party or its agents or
employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party. 

    9.6 Headings. The headings for each article and section in this Agreement have been inserted for the convenience of
reference only and are not intended to limit or expand on the meaning of the language contained in the particular article or section. 

    9.7 Notices. Any notice or other communication required or permitted to be given to either Party hereto shall be in
writing unless otherwise specified and shall be deemed to have been properly given and to be effective on the date of delivery if delivered in person or by facsimile or three (3) days after
mailing by registered or certified mail, postage paid, to the other Party at the following address: 

	If to Rigel:	 	Rigel, Inc.

240 East Grant Avenue

South San Francisco, CA 94080

Attn: Secretary

Fax: 650.624.1101
	

Copy to:	
 	

Cooley Godward, LLP

Five Palo Alto Square, 4th Floor

3000 El Camino Real

Palo Alto, CA 94306

Attn: Robert L. Jones, Esq.

Fax: 650.849.7400
	

If to CG:	
 	

Cell Genesys, Inc.

342 Lakeside Drive

Foster City, CA 94404

Attn: Chief Executive Officer

Fax: 650.358.0803

    9.8 Severability. Whenever possible, each provision of the Agreement will be interpreted in such manner as to be
effective and valid under applicable law, but if any provision of the Agreement is held 

to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of the Agreement. 

    9.9 Entire Agreement of the Parties. The Agreement will constitute and contain the complete, final and exclusive
understanding and agreement of the Parties with respect to the subject matter hereof and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements, whether
oral or written, between the Parties respecting the subject matter. Each Party hereto was represented by counsel in drafting and negotiating this Agreement, and all Parties are deemed to have
contributed to the drafting hereof. 

    9.10 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of
California excluding only laws and rules relating to "choice of law". All Parties to this Agreement hereby consent to the jurisdiction of the courts of the State of California and the Federal District
Court for the Northern District of California for resolution of any disputes that arise hereunder. 

    9.11 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be an original, but
all of which together shall constitute one instrument. 

    In Witness Whereof, the Parties hereto have amended and restated this Agreement as of March 26, 2001. 

	
Cell Genesys, Inc.	
 	

Rigel Pharmaceuticals, Inc.
	

By:	

 	

/s/ ROBERT TIDWELL
	

 	

By:	

 	

/s/ RAUL R. RODRIGUEZ

	

Name:	
 	

Robert Tidwell
	
 	

Name:	
 	

Raul R. Rodriguez

	

Title:	
 	

VP Corporate Dev.
	
 	

Title:	
 	

VP Business Dev.

 
 

APPENDIX A
  EXCLUSIVE LICENSE AGREEMENT    
  

    Exclusive License Agreement made as of January 31, 1996 (the "Effective Date"), by and between Cell
Genesys, Inc. ("Company"), a corporation organized and existing under the laws of the State of Delaware, having an office at 322 Lakeside Drive, Foster City, California 94404, and  The Rockefeller
University ("Rockefeller"), a nonprofit education corporation organized and existing under the laws of the State of New York, having an
office at 1230 York Avenue, New York, New York 10021-6395. 

 
 

Witnesseth:    
  

    Whereas, Rockefeller is the owner by assignment from Warren S. Pear, Martin L. Scott, Garry M. Nolan and David
Baltimore ("Inventors") of the entire right, title and interest in United States Patent Application Serial No. 08/023,909, filed February 22, 1993, entitled Production of High Titer
Helper-Free Retroviruses by Transient Transfection, and in the inventions described and claimed therein ("Licensed Patent Rights"), and in the Biological Materials and related
Know-How, as defined below; 

    Whereas, Rockefeller and the Company entered into a license agreement effective as of October 25, 1994 (the "Prior Agreement"),
pursuant to which Rockefeller granted to the Company a non-exclusive license to use the Licensed Patent Rights, Know-How and Biological Materials for research and commercial
purposes; 

    Whereas, the parties have agreed to expand the scope of the license and rights granted to the Company and therefore have agreed to
terminate the Prior Agreement as of the Effective Date, and enter into this Agreement; 

    Whereas, Rockefeller wishes to offer and grant the Company an exclusive license with regard to the Licensed Patent Rights,
Know-How and the Biological Materials for research and commercial purposes, and seeks to be compensated for the transfer and use of such rights; and 

    Whereas, the Company wishes to license from Rockefeller the Licensed Patent Rights, Biological Materials and Know-How for
commercial development and application as herein defined. 

    Now, Therefore, in consideration of the mutual benefits to be derived hereunder, the parties hereto agrees as follows: 

	1.
	DEFINITIONS.

    The
following terms will have the meanings assigned to them below when used in this Agreement. 

    1.1 "Affiliate" shall mean: 

    (a) any entity owning or controlling, directly or indirectly, at least forty-nine percent (49%) of the stock
normally entitled to vote for election of directors of a party; or 

    (b) any entity at least forty-nine percent (49%) of whose stock normally entitled to vote for election of
directors is owned or controlled, directly or indirectly, by a party. 

    1.2 "Biological Materials" shall mean (i) the ecotropic producer cell line named
[*] which producer cell line was deposited with the American Type Culture Collection as of [*] and has been assigned Accession No.
[*], and any viruses produced thereby; (ii) {Not disclosed by Cell Genesys} Biological Materials shall also include any
direct progeny, mutant, or derivatives of the [* ] {Not disclosed by Cell Genesys} cell lines and the
viruses produced thereby. 

    1.3 "Improvement Technology" means all patent and other intellectual property rights, and
materials relating to inventions, discoveries or improvements to the Licensed Technology licensed to Rockefeller by any academic institution, governmental and other
not-for-profit entity to which Rockefeller grants a non-exclusive research license with regard to the Licensed Technology pursuant to Section 6.3 herein. 

    1.4 "Know-How" shall mean information and data not generally known which are owned
and in the possession of or available to Rockefeller and which it is free to divulge as of the Effective Date regarding the preparation and use of Biological Materials, and pharmacological, biological
and clinical properties of Biological Materials. It is understood that Know-How shall not include any information or data known by the Company prior to receipt of such information or data
from Rockefeller, as shown by reasonable evidence. 

    1.5 "Licensed Patent Rights" shall mean: 

    (a) the patent application(s) concerning the subject matter of this Agreement which are listed on Exhibit A
attached hereto; 

    (b) all patent applications which are divisions, substitutions, continuations,
continuations-in-part, renewals, or additions of the patent applications described in (a) hereof, 

    (c) all foreign counterparts of the applications listed in (a) and (b) hereof; and 

    (d) all patents, including reissues, re-examinations and extensions, which may issue on any of the
preceding. 

    1.6 "Licensed Products" shall mean any and all products the manufacture,
use or sale of which but for the license granted herein would infringe a Valid Claim or are within the scope of a Pending Claim in the country in which such products are made or sold. 

    1.7 "Licensed Technology" shall mean the Licensed Patent Rights, Biological Materials and
Know-How. 

    1.8 "Net Sales" shall mean [*], where [*] shall
mean the amount invoiced by the Company or its sublicensees to customers for Licensed Products less: (i) all trade, cash and quantity credits, discounts, refunds or government rebates,
(ii) amounts for claims, allowances or credits for returns; retroactive price reductions; chargebacks or the like; (iii) packaging, handling fees and prepaid freight, sales taxes, duties
and other governmental charges (including value added tax), but excluding what is commonly known as income taxes; and (iv) provisions for uncollectible accounts determined in accordance with
reasonable accounting practices, consistently applied to all products of the selling party. [*] shall not include sales by the Company to its Affiliates for resale, provided
that if the Company sells a Licensed Product to an Affiliate for resale, [* ] shall include the amounts invoiced by such
Affiliate to third parties on the resale of such Licensed Product. Notwithstanding the foregoing. [*] shall include charges for the separation, transduction and/or expansion of
cells comprising Licensed Products, but notwithstanding any of the foregoing, shall not include charges for apheresis, reinfusion, surgical procedures, hospital stays or other charges not directly
attributed to the Licensed Product or to the ex vivo preparation of the Licensed Product. 

    1.9 "Party" shall mean the Company or Rockefeller, and "Parties" shall mean both the Company and
Rockefeller. 

    1.10 "Pending Claim" shall mean a claim of a pending patent application within the Licensed
Patent Rights. 

    1.11 "Territory" shall mean the entire world. 

    1.12 "Valid Claim" shall mean a claim of an issued and unexpired patent included within the
Licensed Patent Rights, which has not been held unenforceable or invalid by a court or other governmental agency of competent jurisdiction, and which has not been admitted to be invalid or
unenforceable through reissue, disclaimer or otherwise. 

	2.
	Licensed Rights

    2.1 Subject to Section 2.2 below, Rockefeller grants to the Company and its Affiliates the following licenses: 

    (a) an exclusive, worldwide, royalty-bearing license under the Licensed Technology, with the right to grant and
authorize sublicenses, to make, have made, import, have imported, use, sell, offer for sale and otherwise exploit the Licensed Products in any country of the Territory; and 

    (b) a non-exclusive, worldwide, royalty-free, irrevocable license under the Improvement
Technology, with the right to grant and authorize sublicenses, to make, have made, import, have imported, use, sell, offer for sale and otherwise commercialize products and services in any country of
the Territory. 

    2.2 The licenses granted by Rockefeller in Section 2.1 (a) above are subject to any limitations on
Rockefeller's rights arising under the provisions of the following: 

    (a) 35 United States, Section 201 et seq., and regulations and rules promulgated thereunder and any agreements
implementing the provisions thereof, or 

    (b) other applicable laws or regulations to which Rockefeller may be subject; or 

    (c) Rockefeller's Institutional Patent Agreement with the United States Department of Health and Human Services, dated
June 15, 1973, as amended, which is its formal agreement with the United States Government to implement the cited provisions of the U.S. Code. 

    2.3 Rockefeller shall promptly notify the Company of any Improvement Technology of which it acquires knowledge and
provide the Company all available information relating thereto. 

    2.4 The licenses herein granted shall continue for the lives of any issued patents hereunder as the same or the
effectiveness thereof may be extended by any governmental authority, rule or regulation applicable thereto. 

	3.
	Transfer Of Biological Materials And Know-How

    3.1 The parties acknowledge that pursuant to the Prior Agreement, Rockefeller transferred to the Company a quantity of
Biological Materials and such Know-How to allow the Company to establish a viable cell culture of said Biological Materials for the Company's purposes. The Company is permitted to
cultivate and use said Biological Materials, subject to the terms and conditions of this Agreement. On the Effective Date, Rockefeller shall notify the American Type Culture Collection ("ATCC") that
the Company is authorized to receive samples of the Biological Materials deposited with the ATCC and to deliver such materials to the Company at the Company's request, and that the Company has the
right to authorize third parties to receive one or more samples of the Biological Materials, on such terms as the Company may indicate to the ATCC. 

    3.2 Should the Company exhaust the quantity of Biological Materials within six (6) months of the date of
execution hereof, so that a viable cell culture of said Biological Materials no longer exists, Rockefeller shall authorize the ATCC to provide the Company with a quantity of Biological Materials
sufficient to reestablish the Company's viable colony thereof. 

    3.3 Within sixty (60) days of the Effective Date, Rockefeller shall deliver to the Company tangible copies of all
existing Know-How which it did not previously provide to the Company pursuant to the Prior Agreement. 

	4.
	Payments

    4.1 In consideration of the rights and licenses granted hereunder, the Company shall pay or cause to be paid to
Rockefeller amounts as follows: 

    (a) {Not disclosed by Cell Genesys}

    (b) {Not disclosed by Cell Genesys}

    (c) {Not disclosed by Cell Genesys}

    (d) a royalty of [*] of Net Sales of Licensed Products sold by the Company within the scope of a
Valid Claim within the Licensed Patent Rights in the country they are made or sold. 

Notwithstanding
the above, the royalty due Rockefeller on Net Sales of Licensed Products, the manufacture, use or sale of which would not infringe a Valid Claim in the country for which they are sold
but which are within the scope of a Pending Claim in such country, shall be fifty percent (50%) of the royalty due under Section 4. l(d). 

    4.2 In the event that a Licensed Product is sold in combination as a single product with another product whose sale and
use are not covered by the Licensed Patent Rights in the country for which the combination product is sold, Net Sales from such sales, for purposes of calculating the amounts due under
Section 4.1 above, shall be calculated by multiplying the Net Sales of that combination by the fraction A/(A + B), where A is the gross selling price of the Licensed Product, as
the case may be, sold separately, and B is the gross selling price of the other product sold separately. In the event that no such separate sales are made by the Company, Net Sales for royalty
determination shall be as reasonably allocated by the Company between such Licensed Product and such other product, based upon their relative importance and proprietary protection. 

    4.3 Licensed Products sold, leased or otherwise distributed by the Company's sublicensees shall be considered to be
sales, leases or disposals of Licensed Products by the Company for purposes of royalty payments and reports under this Agreement. The obligation to pay royalties pursuant to this Agreement is imposed
only once with respect to the sale of a particular Licensed Product regardless of the number of claims or patents that cover such Licensed Product. The Company shall have no obligation to pay
royalties on Licensed Products used in research and development, in clinical trials or other noncommercial purposes, or distributed as samples. 

    4.4 The Company's obligation to pay royalties hereunder shall continue on a country-by-country
basis until (i) the expiration of the last-to-expire issued patent within the Licensed Patent Rights in such country, or (ii) [*]following
the first commercial sale of a Licensed Product in a country, if no patent covering such Licensed Product has been issued in such country. Thereafter, the Company shall have a fully paid up license
under Licensed Patent Rights, Biological Materials and Know-How to make, have made, use, sell, lease, import, have imported, offer for sale or otherwise exploit the Licensed Product(s) for
any use in that country. 

    4.5 {Not disclosed by Cell Genesys}

    4.6 {Not disclosed by Cell Genesys}

    4.7 Unless this Agreement is terminated earlier, within sixty (60) days following the first achievement by the
Company or a sublicensee of the following milestones with respect to the first Licensed Product within the scope of a Valid Claim within the Licensed Patent Rights, the Company shall pay to
Rockefeller [*] milestone payments as follows: 

	Event
	 	Payment

	Enrollment of first patient in a Company-sponsored [*] clinical trial of a Licensed Product	 	$	[*]
	

Enrollment of first patient in a Company-sponsored [*] clinical trial of a Licensed Product	
 	
$	

[*]
	

Approval of NDA in U.S. of a Licensed Product	
 	
$	

[*]

    4.8 Upon commencement of commercial sales of any Licensed Products which generate a royalty to Rockefeller pursuant to
this Agreement, the Company shall within ninety (90) days of the close of the fiscal semi-annual period, provide semi-annual reports to Rockefeller showing the total Net
Sales of Licensed Products sold, leased or otherwise disposed of during such period and the calculation of royalties thereon. Any royalty then due and payable shall be included with such report. All
reports provided hereunder by the Company shall be the Confidential Information of the Company, subject to Section 7 herein. The Company's records shall be open to inspection by an independent
certified public 

accountant designated by Rockefeller for three (3) years from the submission of such reports and payments, subject to execution of a confidentiality agreement reasonably acceptable to the
Company, once per calendar year at reasonable times, at Rockefeller's expense, for the sole purpose of verifying the accuracy of the reports and royalty payments made by the Company. The accountant
shall report to Rockefeller only whether there has been an underpayment and, if so, the amount thereof. 

	5.
	Times And Currencies Of Payment

    5.1 Royalty payments shall be made in United States dollars or if sales are made in the currency of other countries,
royalties shall be calculated in the currency of such other country and be converted into United States dollars using the applicable exchange rate for sale of U.S. dollars listed by the foreign
exchange desk of the Bank of America on the last day of the applicable reporting period. 

    5.2 If at any time legal restrictions prevent the prompt remittance of part or all royalties by the Company with respect
to any country where a Licensed Product is sold, the Company shall have the right and option to make such payment by depositing the amount thereof in local currency to an account in the name of
Rockefeller in a bank or other depository in such country. 

	6.
	Sublicensees

    6.1 The Company and its Affiliates shall have the right to grant and authorize sublicenses under the Licensed Technology
and Improvement Technology to commercial entities for research purposes and for commercial purposes, including without limitation, to make, have made, import, have imported, use, lease, offer for sale
and sell Licensed Products in the Territory. 

    6.2 The Company shall have the sole discretion to determine the financial and other terms on which any sublicenses shall
be granted under the Licensed Technology, subject to the provisions herein. Any sublicense(s) granted by the Company under this Agreement shall be subject and subordinate to the terms and conditions
of this Agreement, except the financial terms of the sublicense(s) may require greater payments than the financial terms in this Agreement. 

    6.3 Notwithstanding Section 2.1 above, Rockefeller, on behalf of the Company, may continue to grant limited,
non-transferable, research sublicenses to academic institutions, governmental and other not-for-profit entities using the form sublicense agreement attached hereto
as Exhibit B. Rockefeller shall not enter into or agree to enter into any agreement with such an entity which deviates in any way from the form agreement set forth in Exhibit B, without
the prior written consent of the Company. Rockefeller shall provide the Company with a copy of each such research license entered by Rockefeller promptly following the execution of such agreement. 

    6.4 In the event of any termination of this Agreement, any sublicenses granted under or this Agreement shall also
terminate unless such sublicensees provide Rockefeller written notice that they will abide by the applicable terms of this Agreement. 

    6.5 In no event shall a default or breach of a sublicensee of a sublicense granted by the Company pursuant to this
Agreement constitute by a default or breach by the Company of this Agreement or be deemed a valid basis for the termination of this Agreement. 

	7.
	Confidential Information

    7.1 Each Party and its Affiliates and sublicensees shall treat as confidential all Confidential Information received
from the other Party hereto, shall not use such Confidential Information except as expressly set forth herein or otherwise authorized in writing, shall implement reasonable procedures to prohibit the
disclosure, unauthorized duplication, misuse or removal of such Confidential Information and shall not disclose such Confidential Information to any third party except as may be necessary and required
in connection with the rights and obligations of such party under this Agreement, and subject to confidentiality obligations at least as protective as those set forth herein. Without limiting the
foregoing, each of the parties shall use at least the same procedures and degree of care which it uses to prevent the disclosure of its own confidential information to prevent the disclosure of
Confidential Information of the other Party. As used herein, the term "Confidential Information" shall mean any 

information expressly designated as Confidential Information in this Agreement and information disclosed by one Party to another pursuant to this Agreement which is in written, graphic, machine
readable or other tangible form and is marked "Confidential" to indicate its confidential nature. Confidential Information may also include oral information disclosed by one Party to another pursuant
to this Agreement, provided that such information is designated as confidential at the time of disclosure and within thirty (30) days after its oral disclosure is reduced to a written summary
by the disclosing Party, which summary is marked in a manner to indicate its confidential nature and delivered to the receiving Party. 

    7.2 Notwithstanding the above, neither Party has any obligation of confidence under this Agreement with respect to any
information which: 

    (i)  may be demonstrated to have been known to the receiving Party prior to the time of disclosure thereof by the
disclosing Party; or 

    (ii) without breach of this Agreement, has been published or is otherwise available to the public at any time whether
before or after the time of disclosure to such Party; or 

    (iii) is at any time lawfully received by such Party from a third party who has no obligation of confidence to a Party
in respect hereof. 

    7.3 Each Party hereto may disclose another's Confidential Information to the extent such disclosure is reasonably
necessary in filing or prosecuting patent applications, prosecuting or defending litigation, complying with applicable governmental regulations or otherwise submitting information to tax or other
government authorities, making a permitted sublicense or other exercise of its rights hereunder or conducting clinical trials, provided that if a Party is required to make any such disclosure of
another Party's secret or Confidential Information, other than pursuant to a confidentiality agreement, it will give reasonable advance notice to the latter Party of such disclosure requirement and,
will use its best efforts to secure confidential treatment of such information prior to its disclosure (whether through protective orders or otherwise). 

	8.
	Representations And Warranties

    8.1 Rockefeller represents and warrants that: (i) it is a nonprofit corporation duly organized, validly existing
and in good standing under the laws of New York; (ii) the execution, delivery and performance of this Agreement have been duly authorized by all necessary action on the part of Rockefeller;
(iii) it is the sole and exclusive owner of all right, title and interest in the Licensed Patent Rights; (iv) the Licensed Patent Rights are free and clear of any lien, security interest
or restriction on transfer or license; (v) Rockefeller has not previously granted, and will not grant during the term of this Agreement, any right, license or interest in and to the Licensed
Patent Rights, Biological Materials and Know-How, or any portion thereof, in conflict with the rights, exclusive license and interest granted to the Company herein; (vi) it has
complied fully with all requirements of 35 U.S.C. § 201 et seq. and all implementing regulations with respect to perfecting its interest in the Licensed Patent Rights;
(vii) Exhibit A contains a complete and accurate listing of all Licensed Patent Rights existing as of the Effective Date; and (viii) there are no actions, suits, investigations,
claims or proceedings pending in any way relating to the Licensed Patent Rights, Biological Materials or Know-How. 

    8.2 The Company represents and warrants that: (i) it is a corporation duly organized, validly existing and in
good standing under the laws of the State of Delaware; and (ii) the execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part
of the Company. 

    8.3 ROCKEFELLER EXPRESSLY DISCLAIMS ANY AND ALL IMPLIED OR EXPRESS WARRANTIES AND MAKES NO EXPRESS OR IMPLIED WARRANTIES
OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF BIOLOGICAL MATERIALS, LICENSED PROCESSES OR LICENSED PRODUCTS CONTEMPLATED BY THIS
AGREEMENT. FURTHER, ROCKFELLER HAS MADE NO FORMAL INVESTIGATION AND THEREORE CAN MAKE NO REPRESENTATION THAT BIOLOGICAL MATERIALS 

SUPPLIED BY IT OR THE METHODS USED IN MAKING OR USING SUCH MATERIALS ARE NOW OR WILL REMAIN FREE FROM LIABILITY FOR PATENT INFRINGEMENT. 

	9.
	{Not disclosed by Cell Genesys}

    9.1 {Not disclosed by Cell Genesys}

    9.2 {Not disclosed by Cell Genesys}

	10.
	Publicity

    The
Company will not use either directly or by implication the name of Rockefeller, or the name of any member of the faculty or staff thereof for any commercial or promotional
purposes without prior notification and written agreement of Rockefeller. Except as expressly provided herein, the Parties agree not to disclose the terms of this Agreement to any third party without
the prior written consent of the other Party to the fact and form of such disclosure, except as required by securities or other applicable laws, to prospective investors and to such party's
accountants, attorneys and other professional advisors. Notwithstanding the above, the Company may disclose the existence of this Agreement and issue a press release, reasonably acceptable to
Rockefeller, describing this Agreement and the rights granted the Company by Rockefeller under this Agreement, and disclose to actual and potential sublicensees the rights granted the Company by
Rockefeller under this Agreement. 

	11.
	Patents

    11.1 Except as set forth in Section 11.4, the Company shall have the sole right to control the preparation,
filing, prosecution and maintenance of the Licensed Patent Rights, and any interference or opposition proceeding relating thereto, using patent counsel of its choice. The Company shall consult with
Rockefeller regarding the prosecution of any such patent applications, by providing Rockefeller a reasonable opportunity to review and comment on all proposed submissions to any patent office before
submittal, and provided further that the Company shall keep Rockefeller reasonably informed as to the status of such patent applications by promptly providing Rockefeller copies of all communications
relating to such patent applications that are received from any patent office. If the Company informs
Rockefeller in writing that the Company no longer wishes to conduct such activities with regard to any such patent applications or patents in any country, then Rockefeller will be free, at its
discretion and expense to either abandon the subject patent applications or to continue such activities, and the Company shall have no further rights with respect to the applicable patent applications
or patents in such countries. 

    11.2 During the term of the Agreement, the Company shall be responsible for one hundred percent (100%) of the expenses
incurred in connection with the activities set forth in Section 11.1. above. {Not disclosed by Cell Genesys} With respect to patent-related costs
incurred after the Effective Date, the Company shall reimburse Rockefeller within thirty (30) days following invoice for such costs, in a form reasonably acceptable to the Company. 

    11.3 If either Party hereto becomes aware that any Licensed Patent Rights are being or have been infringed by any third
party, such Party shall promptly notify the other Party hereto in writing describing the facts relating thereto in reasonable detail. The Company shall have the initial right, but not the obligation,
to institute, prosecute and control any action, suit or proceeding (an "Action") with respect to such infringement, including any declaratory judgment action, at its expense, using counsel of its
choice; provided, however, during the pendency of any such Action, the Company shall be entitled to place any royalties otherwise due Rockefeller hereunder in a separate account controlled by the
Company. If the pertinent Licensed Patent Rights are found invalid or unenforceable in such an Action, or any appeal thereof, the Company may retain the amounts placed in such account without further
obligation to Rockefeller with regard thereto. If the Licensed Patent Rights are not held invalid or unenforceable in such an Action, or any appeal thereof, the Company shall promptly pay the amounts
deposited in such account to Rockefeller. Any amounts recovered from third parties in any such Action shall be retained by the Company. In the event the Company fails to initiate or defend any Action
involving the Licensed Patent Rights within one (1) year of receiving notice of any commercially 

significant infringement, Rockefeller shall have the right, but not the obligation, to initiate and control such an Action, and the Company shall cooperate reasonably with Rockefeller, at
Rockefeller's request, in connection with any such Action. Any amounts recovered in such Action shall be used first to reimburse the Company and Rockefeller for the expenses incurred in connection
with such Action, and any remainder retained by Rockefeller. 

    11.4 In the event the parties believe an interference may be declared or an interference is declared between any patent
application or patent within the Licensed Patent Rights and any patent application or patent owned or controlled by the Company relating to the production of high titer retroviruses, the parties agree
to amicably settle any such prospective or actual interference in accordance with the procedure set forth on Exhibit C. The Company shall have the exclusive right to initiate such settlement
procedure after consultation with Rockefeller. In the event of any such prospective or actual interference and the settlement thereof, each Party shall pay its own costs associated therewith and the
parties shall equally share the costs of any arbitration, including without limitation, administration and arbitrator fees. It is understood and agreed that in the event an interference is declared,
neither Patty shall have an obligation to participate in such a proceeding, but each hereby acknowledges that it
understands that a failure to participate may result in an adverse outcome which could have a material adverse impact on such Party. It is further understood and agreed that any patent applications
and patents within the Licensed Patent Rights which are involved in any interference shall remain subject to the license granted the Company herein. 

	12.
	Licensed Product Liability

    The
Company agrees to indemnify, defend and hold harmless Rockefeller and its trustees, officers, agents, faculty, employees, and students (the "Indemnitees"), from any and all
liability arising from injury or damage to persons or property resulting directly or indirectly from the Company's acquisition, use, manufacture, sublicense or sale of any Licensed Product covered by
Licensed Patent Rights or Know-How licensed hereunder. Notwithstanding the foregoing, the Company expressly retains any and all claims it may have against Indemnitees arising from
Indemnitees' negligence or willful misconduct. The Company's obligation to indemnify the Indemnitees under this Section 11 shall not apply unless the indemnified Party promptly notifies the
Company of any claim or liability subject to this Section 12 and cooperates fully with the Company in the defense of any such claim or proceeding. The Company further agrees to obtain, prior to
the first commercial sale of a Licensed Product, and maintain in force for at least fifteen (15) years following the last sale of a Licensed Product, product liability insurance coverage of at
least one million ($1,000,000) dollars or a lesser amount as appropriate to the risk as determined by reference to reliable standards in the industry, such insurance to specifically name Rockefeller
as an additional insured. 

	13.
	Notices

    Any
notice required to be given pursuant to this Agreement shall be in writing and may be made by personal delivery or by registered or certified mail, return receipt requested, by
one Party to the other Party at the addresses noted below: 

In
the case of the Company, notice should be sent to:

Cell Genesys, Inc.

322 Lakeside Drive

Foster City, California 94404

Attn: Senior Vice President, Corporate Development

In the case of Rockefeller, notice should be sent to:

The Rockefeller University

1230 York Avenue

New York, New York 10021

Attn: Office of the General Counsel 

	14.
	Law To GovernThis Agreement shall be interpreted and governed in accordance with the
laws of the State of New York.

	15.
	AssignmentThis Agreement may not be assigned by either Party without the prior
written consent of the other; provided, however, the Company may assign this Agreement in connection with the transfer of all or substantially all of
its business relating to the subject matter of this Agreement whether by sale, merger, operation of law or otherwise.

	16.
	Termination

    16.1 The Company shall have the right to terminate this Agreement at any time with respect to any Licensed Patent Right
or any country upon ninety (90) days prior written notice to Rockefeller. Such termination shall automatically terminate the license rights provided in Section 2 with respect to such
Licensed Patent Rights hereof in such country but shall not relieve the Company of the obligation to pay royalties for any period prior to the effective date of termination. 

    16.2 Either Party may terminate this Agreement in the event of a material breach by the other Party which is not cured
within a reasonable time, provided only that the offending Party is given notice of the breach and not less than ninety (90) days in which to cure such breach. 

    16.3 Sections 2.4, 6.4 and 24.3 and Articles 7, 8, 10, 12, 14, 17 and 25 shall survive expiration or termination of this
Agreement for any reason. 

	17.
	Resolution Of Disputes

    The
Parties agree that in the event of it dispute between them arising from, concerning, or in any way relating to this Agreement, the Parties shall undertake good faith efforts to
resolve the same amicably between themselves. 

	18.
	Force Majeure

    The
Parties shall not be liable in any manner for failure or delay in fulfillment of all or part of this Agreement, directly or indirectly caused by acts of God, governmental orders
or restrictions, war, war-like conditions, revolution, riot, looting, strike, lockout, fire, earthquake, flood or other similar or dissimilar cause or circumstances beyond the
nonperforming Party's control. The nonperforming Party shall promptly notify the other Party of the cause or circumstance and shall recommence its performance of its obligations as soon as practicable
after the cause or circumstance ceases. 

	19.
	Binding Upon Successors And Assigns

    Subject
to the limitations on assignment herein, this Agreement shall be binding upon and inure to the benefit of successors in interest or assigns of Rockefeller and the Company. Any
such successor or assignee of a Party's interest shall expressly assume in writing the performance of all the terms and conditions of this Agreement to be performed by said Party. 

	20.
	Independent Contractors

    The
relationship between Rockefeller and the Company is that of independent contractors. Rockefeller and the Company are not joint venturers, partners, principal and agent, master and
servant, employer or employee, and have no other relationship other than independent contracting parties. Rockefeller shall have no power to bind or obligate the Company in any manner, other than as
is expressly set forth in this Agreement. Likewise, the Company shall have no power to bind or obligate Rockefeller in any manner, other than as is expressly set forth in this Agreement. 

	21.
	Severability

    If
any provision of this Agreement is ultimately held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any
way be affected or impaired thereby. 

	22.
	No Waiver

    Any
delay in enforcing a Party's rights under this Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such Party's rights to the
future enforcement of its rights
under this Agreement, excepting only as to an express written and signed waiver as to a particular matter for a particular period of time. 

	23.
	No Implied Obligations

    It
is understood and agreed that nothing in this Agreement shall be deemed to prevent the Company from commercializing technology or products similar to or competitive with the
Licensed Technology or the Licensed Products. Nor shall anything in this Agreement impair the right of the Company to independently acquire, license, develop or have others develop for it technology
performing similar or equivalent functions as the Licensed Technology, or to develop, market or distribute products based on such technology in addition to or in lieu of the Licensed Products. 

	24.
	Compliance With Laws. Regulations And Standards

    24.1 The Company recognizes that the use of Biological Materials carries with it certain safety risks to both the
environment and the population that are inherent in such materials, and shall exercise prudent scientific laboratory procedures in the use of said Biological Materials. 

    24.2 The inventors and Rockefeller recognize and have advised that the Biological Materials may be used to create
infectious retroviruses with a broad host range, that the supplied materials may be used to create retroviruses that can infect human cells in both vitro and in vivo, that the Biological Materials and
all materials derived thereof should be handled and used with all due care in accordance with generally acceptable scientific guidelines establishing appropriate precautions and approved by the
Institutional Biosafety Committee or similar authority at the Company. 

    24.3 The Company shall bear all risk to the Company and/or to any others resulting from use, directly or indirectly, to
which the Company puts the Biological Materials or any progeny or cells or cell lines derived from it. 

	25.
	No Consequential Damages

    IN
NO EVENT SHALL EITHER PARTY BE LIABLE FOR SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF ANY BREACH OF THIS AGREEMENT. 

	26.
	Entire Understanding

    This
Agreement with its Exhibits represents the entire understanding between the Parties with respect to the subject matter hereof and supersedes any other agreement, expressed or
implied, by the Parties with respect to the Licensed Patent Rights, Biological Materials, Know-How and Improvement Technology, and supersedes and merges all prior negotiations, discussions
and agreements, including without limitation, the Prior Agreement between the parties. This Agreement may not be amended or modified except in a written document signed by authorized representatives
of the Parties. 

    In Witness Whereof, the Parties have caused this Agreement to be duly executed as of the day and year first above written. 

	 	 	Cell Genesys, Inc.
	

 	
 	

By:	
 	

/s/ R. SCOTT GREER

	

 	
 	

Title:	
 	

Senior Vice President

Corporate Development
	

 	
 	

Date:	
 	

February 2, 1996
	

 	
 	
The Rockefeller University
	

 	
 	

By:	
 	

/s/ WILLIAM H. GRIESAR

	

 	
 	

Title:	
 	

Vice President and General Counsel
	

 	
 	

Date:	
 	

January 31, 1996

 
 

EXHIBIT "A"
  LICENSED PATENT RIGHTS    
  

    United States Serial No. 08/023,909 

    PCT
Application No. PCT/US94/01983 

 
 

AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT    
  

    This Amendment to Exclusive License Agreement ("Amendment"), effective as of November 3, 1998, by and between Cell Genesys, Inc.,("Company"), a
corporation organized and existing under the laws of the State of Delaware, having an office at 342 Lakeside Drive, Foster City, California 94404, and The Rockefeller University ("Rockefeller"), a
nonprofit education corporation organized and existing under the laws of the State of New York, having an office at 1230 York Avenue, New York, New York 10021-6395 (Company and Rockefeller
collectively, the "Parties"). 

 
 

Background    
  

    The Parties desire to amend that certain Exclusive License Agreement by and between Company and Rockefeller effective as of January 31, 1996 (the
"Agreement") as set forth herein below. 

    Now, Therefore, the Parties agree as follows: 

	1.
	Amendment. This Amendment hereby amends the Agreement to incorporate the terms and conditions set forth in this Amendment. The
relationship of the Parties shall continue to be governed by the terms and conditions of the Agreement, as amended herein; and in the event that there is any conflict between the terms and conditions
of the Agreement and this Amendment, the terms and conditions of this Amendment shall control. As used in this Amendment, all capitalized terms shall have the meanings defined for such terms in this
Amendment or, if not defined in the Amendment, the meanings defined in the Agreement.

	2.
	Modification To The Agreement. 

2.1 Section 4.6 of the Agreement is hereby amended to read in its entirety as follows: 

"4.6 Commercial Sublicenses. It is understood and agreed that Company shall have the right, at its sole discretion, to grant Commercial Sublicenses to
third parties {Not disclosed by Cell Genesys}. As used herein, "Commercial Sublicense" shall mean Commercial Target Sublicenses and any other sublicense
right granted under the Licensed Technology; provided, however, Commercial Sublicenses shall exclude rights granted by Company to a third party pursuant to an agreement substantially in the form of
Exhibit D to this Agreement (i.e., research sublicenses)." 

2.2 The Agreement is hereby amended to add the following new Section 4.9: 

"4.9 Commercial Target Sublicenses. Subject to the terms and conditions set forth in this Section 4.9 below and without limiting the provisions
of Section 4.6 above or Article 6 below, Company shall have the right to grant and authorize Commercial Target Sublicenses to third parties (each such third party, a "Commercial Target
Sublicensee") on terms and conditions as Company deems appropriate in its sole discretion. 

    (a) Milestone and Maintenance Fees. In addition to amounts payable pursuant to Section 4.3 above and in consideration of
Company's right to grant and authorize Commercial Target Sublicenses pursuant to this Section 4.9 {Not disclosed by Cell Genesys}. Payments due
under this Section 4.9(a) shall be due and payable within sixty (60) days after the calendar quarter in which the Milestone Fee or Maintenance Fee, as applicable, is received by Company  {Not disclosed by Cell
Genesys}. 

    (b) Terms. For purposes of this Section 4.9 the following capitalized terms shall have the following meanings. "Commercial
Target Sublicense" shall mean a sublicense under the Licensed Technology that includes the right to conduct Target Validation using the Licensed Technology. "Target Validation" shall mean the process
by which the function of nucleotide sequences are identified, determined and/or confirmed; and/or the function of nucleotide sequences are identified, determined and/or confirmed as being significant
in a disease or other biological pathway in which pharmacological or other intervention is sought to affect the function of that pathway. {Not disclosed by Cell
Genesys}. 

    (c) Survival. Subject to Section 6.4 below, Commercial Sublicenses, including Commercial Target Sublicenses, shall survive the
termination of this Agreement, provided that the Commercial Sublicensee or Commercial Target Sublicensee, as the case may be, agrees to be bound by the applicable terms and conditions of this
Agreement." 

	3.
	Entire Agreement. Together the Agreement (including the Exhibits thereto) and this Amendment constitute the entire agreement between
the Parties in connection with the subject matter thereof and supersede all prior and contemporaneous agreements, understandings, negotiations and discussions, whether oral or written, of the Parties. 

    In Witness Whereof, the Parties have executed this Amendment. 

	Cell Genesys, Inc.	 	The Rockefeller University
	

By:	
 	

/s/ BRUCE A. HIRONAKA
	
 	

By:	
 	

/s/ WILLIAM A. GRIESAR

	Title:	 	Vice President, Corp. Devel.
	 	Title:	 	Vice President and General Counsel

	Date:	 	November 16, 1998
	 	Date:	 	11/3/98

 
 

APPENDIX B
  BOSC 23 CELL LINE    
  

	CGI Docket Number	 	Application, Patent Number or Publication Number	 	Filing Data, Grant date, or Publication Date	 	Title/Inventors
	The Rockefeller University	 	PCTWO94/19478 (US application corresponding to the PCT)	 	 	 	Production of High Titer Helper-Free Retroviruses by Transient Transfection Pear, et al.
	The Rockefeller University	 	US 08/693,160	 	6/12/96	 	Production of High Titer, Helper-Free Retroviruses by Transient Transfection Pear et al.

 
 

KATTM    
  

	CGI Docket Number	 	Application, Patent Number or Publication Number	 	Filing Data, Grant date, or Publication Date	 	Title/Inventors
	CELL 13.0	 	US 5,834,256

(Patent)	 	November 10, 1998	 	Method for Production of High Titer Virus & High Efficiency of Retroviral Mediated Transduction of Mammalian Cells Finer et al.
	CELL 13.1	 	US 5,686,279

(Patent)	 	November 11, 1997	 	Method for Production of High Titer Virus & High Efficiency of Retroviral Mediated Transduction of Mammalian Cells Finer et al.
	CELL 13.1 PCT	 	WO 94/29438	 	December 22, 1994	 	Method for Production of High Titer Virus & High Efficiency of Retroviral Mediated Transduction of Mammalian Cells Finer et al.
	CELL 13.2	 	US 5,858,740

(Patent)	 	January 12, 1999	 	Method of Production of High Titer Virus & High Efficiency of Retroviral Mediated Transduction of Mammalian Cells Finer et al.
	CELL 13.3	 	US 08/517,488	 	August 21, 1995	 	Method for Production of High Titer Virus & High Efficency of Retroviral Mediated Transduction of Mammalian Cells Finer et al.
	CELL 13.3 PCT	 	WO 97/07225	 	February 21, 1997	 	Method for Production of High Titer Virus & High Efficiency of Retroviral Mediated Transduction of Mammalian Cells Finer et al.
	CELL 13.5

(will be dropped if 13.3 is allowed)	 	US 09/266,956	 	March 11, 1999	 	Method for Production of High Titer Virus & High Efficiency of Retroviral Mediated Transduction of Mammalian Cells Finer et al.
	 	 	US 08/914,893	 	8/20/97	 	Method of Production of High Titer Virus & High Efficiency of Retroviral Mediated Transduction of Mammalian Cells. Finer, et al.

 
 

APPENDIX C
    
  

  
 

    RIGEL BIOLOGICAL MATERIALS    
  

    [*] Vectors: 

    [*] 

 
 

APPENDIX D
  NOLAN AND NOLAN/ROTHENBERG PATENTS    
  

    U.S. Patent Application No. 08/589,109, entitled "Methods for Screening for Transdominant Effector Peptides and RNA Molecules" (the Nolan/Rothenberg
Patent Application). 

    U.S.
Patent Applications Nos. 08/789,333, 08/589,911 and 08/963,368, entitled, "Methods for Screening for Transdominant Intracellular Effector Peptides and RNA Molecules" (the Nolan
Patent Application). 

APPENDIX E  

 LICENSE AGREEMENT  

 BY AND BETWEEN  

 THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY  

 AND  

 RIGEL PHARMACEUTICALS, INC.  

APPENDIX E

LICENSE AGREEMENT  

    Effective as of June 1, 1999 (the "Effective Date"), The Board of Trustees of the Leland Stanford Junior
University, a body having corporate powers under the laws of the State of California ("STANFORD") and Rigel Pharmaceuticals,
Inc., a Delaware corporation having a principle place of business at 240 East Grand Avenue, South San Francisco, CA 94080 ("RIGEL"), agree as follows: 

Recitals  

    A.  STANFORD owns certain [*] cell lines and
derivatives thereof and biological components related thereto. 

    B.  RIGEL desires to obtain a non-exclusive license to such materials for use in the Field, with the right
to grant one non-exclusive sublicense to Cell Genesys, Inc. 

1.  Definitions.  

    1.1 "Cell Genesys" means Cell Genesys, Inc., a Delaware corporation, having a principal place of business at 342
Lakeside Drive, Foster City, CA 94404. 

    1.2 "Field" means any and all fields of use, including, without limitation, any research or commercial field of use. 

    1.3 "Licensed Biological Materials" means the materials listed on Exhibit A. 

    1.4 "Licensed Know-How" means: 

	(a)
	any and all tangible or intangible know-how, trade secrets, inventions (whether or not patentable), processes, data, and
other information owned by STANFORD as of the Effective Date that are necessary or useful for the use of the Licensed Biological Materials; and

	(b)
	any modifications or progeny of the information and materials in subsection (a) above that STANFORD may elect to provide to
RIGEL at STANFORD's sole and exclusive discretion. 

    1.5 "Patent" shall mean all foreign and domestic patents (including, without limitation, extensions, reexaminations,
reissues, renewals and inventors certificates) and patents issuing from patent applications (including substitutions, provisionals, divisionals, continuations and
continuations-in-part). 

2.  Grant; Transfer Of Licensed Biological Materials.  

    2.1 STANFORD hereby grants, and RIGEL hereby accepts, a worldwide, non-exclusive license (without the right
to sublicense except to Cell Genesys in the field of human and/or animal gene therapy as provided in Article 8) under STANFORD's right, title and interest in the Licensed Biological Materials
to conduct research and development and to use the Licensed Biological Materials to make, have made, use, import, offer for sale and sell products in the Field. 

    2.2 STANFORD hereby grants, and RIGEL hereby accepts, a worldwide, non-exclusive license (without the right
to sublicense except to Cell Genesys in the field of human and/or animal gene therapy as provided in Article 8) under STANFORD's right, title and interest in the Licensed Know-How
to use the Licensed Know-How in the Field. 

    2.3 STANFORD shall have the right to use the Licensed Know-How and the Licensed Biological Materials for its
own bona fide research, including sponsored research and collaborations. In addition, STANFORD shall have the right to distribute the Licensed Biological Materials. 

    2.4 Promptly after the Effective Date, STANFORD shall transfer to RIGEL such quantities of the Licensed Biological
Materials as RIGEL shall reasonably request. Thereafter, STANFORD shall transfer to RIGEL such additional quantities of Licensed Biological Materials as RIGEL shall 

reasonably request in the event that RIGEL's stock of the Licensed Biological Materials is destroyed or contaminated. 

3.  License Royalties.  

    3.1 In partial consideration for the license granted by STANFORD to RIGEL under Section 2.1, RIGEL agrees to pay
to STANFORD the following: 

    (a) An initial, nonrefundable license issue royalty of  [*], which amount shall be paid within thirty (30) days after the Effective Date. 

    (b) A royalty payment equal to [*] on each of
the first three (3) anniversaries of the Effective Date. 

    After
the third (3rd) anniversary of the Effective Date, the sublicense shall be considered perpetual and fully paid-up. 

    3.2 If RIGEL grants to Cell Genesys a sublicense under the Licensed Biological Materials to use and sell products in the
field of human and/or animal gene therapy, RIGEL shall pay to STANFORD during the term of such sublicense a sublicense fee as follows: 

	Upon signing of the sublicense	 	$[*]
	On each of the first three (3) anniversaries of the effective date of such sublicense	 	$[*]
	On the 4th, 5th and 6th anniversaries of the effective date of such sublicense	 	$[*]

After
the sixth (6th) anniversary of the effective date of such sublicense, the sublicense shall be considered perpetual and fully paid-up. 

4.  Patents; New Inventions.  

    Subject to the terms and conditions of this Agreement, any patentable inventions or discoveries conceived or reduced to practice by the employees, agents or
consultants of one party during the course of the Agreement ("Sole Inventions") shall be the property of such party. Any patentable inventions or discoveries conceived or reduced to practice jointly
by employees, agents or consultants of STANFORD and RIGEL as determined in accordance with United States rules of inventorship ("Joint Inventions") during the course of and pursuant to this Agreement
shall be owned jointly by STANFORD and RIGEL, each to own an undivided one-half (1/2) interest in such Joint Invention. Each party shall cooperate with the other in
completing any patent applications relating to Joint Inventions, and in executing and delivering any instrument required to assign, convey or transfer to such other party its undivided
one-half (1/2) interest. 

5.  Warranties.  

    5.1 STANFORD's Office of Technology Licensing represents and warrants that to the best of its knowledge as of the
Effective Date, STANFORD has not sought or obtained patent protection of the Licensed Biological Materials or any use thereof in the Field. 

    5.2 STANFORD's Office of Technology Licensing represents and warrants that as of the Effective Date, it has no knowledge
of claims by third parties that the use of the Licensed Biological Materials infringes any patents, copyrights or other rights of third parties. 

    5.3 STANFORD represents and warrants that it has all right, power and authority necessary to grant the licenses set
forth in Article 2 to RIGEL. 

    5.4 RIGEL agrees that nothing in this Agreement grants RIGEL any express or implied license or right under or to: 

    (a) U.S. Patent 4,656,134, entitled "Amplification of Eucaryotic Genes" or any patent application corresponding thereto;
or 

    (b) U.S. Patent 5,070,012, entitled "Monitoring of Cells and Trans-Activating Transcription Elements" or any patent
application corresponding thereto; or 

    (c) U.S. Patent 5,804,387, entitled "FACS-Optimized Mutants of the Green Fluorescent Protein (GFP) or any
patent application corresponding thereto. 

    5.5 STANFORD agrees that nothing in this Agreement grants STANFORD any express or implied license or right under or to
U.S. Patent Application Nos. 08/789,333, 08/589,911, or 08/963,368, entitled "Method for Screening for Transdominant Intracellular Effector Peptides and RNA Molecules," or any continuations,
divisionals or continuation-in-parts thereof or any patents which may issue therefrom. 

    5.6 Except as provided in Sections 5.1, 5.2 and 5.3 and as otherwise expressly set forth in this Agreement, nothing in
this Agreement will be construed as a warranty or representation that anything made, used, sold, or otherwise disposed of under any license granted in this Agreement is or will be free from
infringement of patents, copyrights, and trademarks of third parties; conferring rights to use in advertising, publicity, or otherwise any trademark or the name of "STANFORD"; or granting by
implication, estoppel, or otherwise any licenses or rights under patents of STANFORD. 

    5.7 EXCEPT AS EXPRESSLY SET FORTH IN THE AGREEMENT, STANFORD MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY
KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE LICENSED BIOLOGICAL MATERIALS OR LICENSED
KNOW-HOW WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHTS, OR ANY OTHER EXPRESS OR IMPLIED WARRANTIES. 

6.  Indemnity.  

    6.1 RIGEL agrees to indemnify, hold harmless, and defend STANFORD, UCSF-Stanford Health Care and Stanford
Health Services and their respective trustees, officers, employees, students, and agents against any and all claims by third parties for death, illness, personal injury, property damage, and improper
business practices arising out of the manufacture, use, sale, or other disposition of the
Licensed Biological Materials or any products arising or derived from Licensed Biological Materials, by RIGEL or RIGEL's sublicensee(s) or customers. 

    6.2 STANFORD shall not be liable for any indirect, special, consequential or other damages whatsoever, whether grounded
in tort (including negligence), strict liability, contract or otherwise. STANFORD shall not have any responsibilities or liabilities whatsoever with respect to products arising or derived from
Licensed Biological Materials by RIGEL. 

    6.3 RIGEL shall at all times comply, through insurance or self-insurance, with all statutory workers'
compensation and employers' liability requirements covering any and all employees with respect to activities performed under this Agreement. 

    6.4 In addition to the foregoing, RIGEL shall maintain Comprehensive General Liability Insurance, including Products
Liability Insurance, with reputable and financially secure insurance carrier(s) to cover the activities of RIGEL and its sublicensee(s) in the amounts and during the periods specified herein. Such
insurance shall provide minimum limits of liability of One Million Dollars ($1,000,000) as of the first anniversary of the date upon which RIGEL first leases a facility in which it will conduct
research and development activities, and of Five Million Dollars ($5,000,000) as of the commencement of human clinical trials. Such insurance shall include STANFORD, UCSF-Stanford Health
Care and Stanford Health Services, their trustees, directors, officers, employees, students, and agents as additional insureds. Such insurance shall be written to cover claims incurred, discovered,
manifested or made during or after the expiration of this Agreement. At STANFORD's request, RIGEL shall furnish a Certificate of Insurance evidencing primary coverage and requiring thirty
(30) days prior written notice of cancellation or material change to STANFORD. RIGEL shall advise STANFORD, in writing, that it maintains excess liability coverage (following form) over primary 

insurance for at least the minimum limits set forth above. All such insurance of RIGEL shall be primary coverage; insurance of STANFORD, UCSF-Stanford Health Care or Stanford Health
Services shall be excess and noncontributory. 

7.  STANFORD Names And Marks.

    RIGEL
agrees not to identify STANFORD in any promotional advertising or other promotional materials to be disseminated to the pubic or any portion thereof or to use the name of any
STANFORD faculty member, employee, or student or any trademark, service mark, trade name, or symbol of STANFORD, UCSF-Stanford Health Care or Stanford Health Services, or that is
associated with any of them, without STANFORD's prior written consent, except as required by law. STANFORD shall not unreasonably withhold consent under this Section 7. 

8.  Sublicense(s).

    8.1 Subject to the provisions of this Article 8, RIGEL may grant a sublicense to the license rights granted to
RIGEL by STANFORD in Sections 2.1 and 2.2 to Cell Genesys solely in the field of human and/or animal gene therapy. 

    8.2 Any sublicense granted by RIGEL to Cell Genesys under this Agreement shall be subject and subordinate to terms and
conditions of this Agreement, except: 

    (a) Sublicense terms and conditions shall reflect that any sublicensee(s) shall not grant a sublicense to a third party;
and 

    (b) The financial obligations of any sublicensee to RIGEL specified in the sublicense(s) may be different from those
obligations set forth in this Agreement. 

    Any
such sublicense(s) also shall expressly include the provisions of Articles 5 and 6 for the benefit of STANFORD and shall survive any termination of this Agreement. 

    8.3 RIGEL agrees to provide STANFORD with a copy (with financial terms redacted) of any sublicense granted to Cell
Genesys pursuant to this Article 8 and written notice of the effective date of any termination of such sublicense prior to the expiration of the Term (as defined in Section 9.1). 

9.  Term And Termination.

    9.1 The term of this Agreement shall commence upon the Effective Date and shall expire upon the later of: (a) the
expiration of the last to expire of any Patents owned by STANFORD at any time which claim inventions in the Licensed Biological Materials or the Licensed Know-How; or (b) twenty
(20) years from the Effective Date (the "Term"). In addition, RIGEL may terminate this Agreement prior to the expiration of the Term by giving STANFORD notice in writing at least thirty
(30) days in advance of the effective termination date selected by RIGEL. 

    9.2 Either party may terminate this Agreement prior to the expiration of the Term if the other party is in material
breach of any provision hereof and fails to remedy any such default or breach within thirty (30) days after written notice thereof to the breaching party. 

    9.3 Surviving the expiration of the Term are: 

    (a) Any cause of action or claim of RIGEL or STANFORD, accrued or to accrue, because of any breach or default by the
other party prior to the expiration of the Term; and 

    (b) Articles 4, 5, 6, 7 and 11; and 

    (c) Article 8 and Sections 2.1 and 2.2; and the licenses granted thereunder shall be deemed perpetual and fully
paid-up. 

    9.4 Surviving any termination of this Agreement are: 

    (a) Any cause of action or claim of RIGEL or STANFORD, accrued or to accrue, because of any breach or default by the
other party prior to the termination of this Agreement; and 

    (b) Articles 4, 5, 6, 7, 8 and 11 and Section 3.2; and 

    (c) Sections 2.1 and 2.2 if RIGEL has fulfilled all of its payment obligations to STANFORD under Section 3.1
prior to such termination; and the licenses granted thereunder shall be deemed perpetual and fully paid-up. 

10. Assignment.

    This
Agreement may not be assigned by either party without the express written consent of the other party, except that RIGEL may assign the Agreement in connection with a merger,
consolidation or sale of all or substantially all of RIGEL's assets. 

11. Arbitration.

    11.1 Any controversy arising under or related to this Agreement, and any disputed claim by either party against the
other under this Agreement excluding any dispute relating to patent validity or infringement arising under this Agreement, shall be settled by arbitration in accordance with the Licensing Agreement
Arbitration Rules of the American Arbitration Association. 

    11.2 Upon request by either party, arbitration will be by a third party arbitrator mutually agreed upon in writing by
RIGEL and STANFORD within thirty (30) days of such arbitration request. Judgment upon the award rendered by the arbitrator shall be final and nonappealable and may be entered in any court
having jurisdiction thereof. 

    11.3 The parties shall be entitled to discovery in like manner as if the arbitration were a civil suit in the California
Superior Court. 

    11.4 Any arbitration shall be held at Stanford, California, unless the parties hereto mutually agree in writing to
another place. 

12. Notices.

    All
notices under this Agreement shall be deemed to have been fully given when done in writing and deposited in the United States mail registered or certified, and addressed as
follows: 

	To STANFORD: Office of Technology Licensing	 	Stanford University

900 Welch Road, Suite 350

Palo Alto, CA 94304-1850

Attention: Director
	To RIGEL: Rigel Pharmaceuticals, Inc.	 	240 East Grand Ave.

South San Francisco, CA 94080

Attention: President

    Either
party may change its address upon written notice to the other party. 

13. Waiver.

    None
of the terms of this Agreement can be waived except by the written consent of the party waiving compliance. 

14. Applicable Law.

    This
Agreement shall be governed by the laws of the State of California applicable to agreements negotiated, executed and performed wholly within California. Any claim or controversy
arising out of or 

related to this Agreement or any breach hereof shall be submitted to a court of applicable jurisdiction in the State of California, and each party hereby consents to the jurisdiction and venue of such
court. 

15. Disclaimer Of Agency. 

    Neither
party is, or will be deemed to be, the legal representative or agent of the other, nor shall either party have the right or authority to assume, create, or incur any third
party liability or obligation of any kind, express or implied, against or in the name of or on behalf of another except as expressly set forth in this Agreement. 

16. Severability.

    If
any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not
be in any way affected or impaired thereby. 

17. Entire Agreement.

    This
Agreement, together with the Exhibit attached hereto, embodies the entire understanding of the parties and shall supersede all previous communications, representations or
understandings, either oral or written, between the parties relating to the subject matter hereof. No amendment or modification hereof shall be valid or binding upon the parties unless made in writing
and signed by duly authorized representatives of both parties. 

18. Counterparts.

    This
Agreement may be executed in counterparts, with the same force and effect as if the parties had executed the same instrument. 

    In Witness Whereof, the parties hereto have executed this Agreement in duplicate originals by their duly authorized officers or
representatives. 

	The Board of Trustees of the

Leland Stanford Junior University	 	Rigel Pharmaceuticals, Inc.
	By:	 	/s/ KATHERINE KU   
	 	By:	 	/s/ DONALD W. PERRYMAN   

	Name:	 	Katherine Ku
	 	Name:	 	Donald W. Perryman

	Title:	 	Director, Technology Licensing
	 	Title:	 	VP, Business Development
 June 9,1999

Exhibit A  

LICENSED
BIOLOGICAL MATERIALS 

[*]
Vectors: 

[*] 

APPENDIX F  

	Application, Patent

Number or

Publication Number
	 	Filing Date, Grant Date, or

Publication Date
	 	Title/Inventors

	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]

APPENDIX G  

RESEARCH PLAN  

[*]

(6
pages of text omitted here) 

APPENDIX H  

LIST OF FTEs  

[*] 

[*] 

[*] 

APPENDIX I

THIRD PARTY PATENTS  

[*]

[*]=Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 24d-2 of the Securities Exchange Act of 1934, as amended.  

QuickLinks

APPENDIX A EXCLUSIVE LICENSE AGREEMENT

Witnesseth

EXHIBIT "A" LICENSED PATENT RIGHTS

AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT

Background

APPENDIX B BOSC 23 CELL LINE

KATTM

APPENDIX C

RIGEL BIOLOGICAL MATERIALS

APPENDIX D NOLAN AND NOLAN/ROTHENBERG PATENTS

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}]]